TYK2
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
Y Sites Probabilities
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A1L429 | Y10 | Sugiyama | GAGE12B; GAGE12C; GAGE12D; GAGE12E | ___________MSWRGRsTyyWPRPRRYVQPPEMIGPMRPE |
| A5A3E0 | Y1062 | Sugiyama | POTEF A26C1B | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCL_______ |
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| A6NDE8 | Y10 | Sugiyama | GAGE12H | ___________MSWRGRsTyyWPRPRRYVQPPEMIGPMRPE |
| A6NER3 | Y10 | Sugiyama | GAGE12J | ___________MSWRGRsTyyWPRPRPYVQPPEMIGPMRPE |
| O14910 | Y133 | Sugiyama | LIN7A MALS1 VELI1 | KTDEGLGFNVMGGKEQNsPIyIsRIIPGGVAERHGGLKRGD |
| O14950 | Y156 | Sugiyama | MYL12B MRLC2 MYLC2B | DEEVDELyREAPIDKKGNFNyIEFtRILKHGAKDKDD____ |
| O14979 | Y167 | Sugiyama | HNRNPDL HNRPDL JKTBP | DGKMFIGGLSWDTsKKDLtEyLSRFGEVVDCtIKTDPVTGR |
| O15304 | Y162 | EPSD|PSP | SIVA1 SIVA | CWGCGSVACTLCGLVDCSDMyEKVLCTSCAMFET_______ |
| O15304 | Y53 | EPSD|PSP | SIVA1 SIVA | RySQEVFEKTKRLLFLGAQAyLDHVWDEGCAVVHLPEsPKP |
| O43448 | Y311 | Sugiyama | KCNAB3 KCNA3B | LITSKYDGRVPDTCRASIKGyQWLKDKVQSEDGKKQQAKVM |
| O43707 | Y212 | Sugiyama | ACTN4 | WKDGLAFNALIHRHRPELIEyDKLRKDDPVTNLNNAFEVAE |
| O43852 | Y187 | Sugiyama | CALU | GDLIATKEEFtAFLHPEEyDyMKDIVVQEtMEDIDKNADGF |
| O43852 | Y263 | Sugiyama | CALU | KNRDGKMDKEEtKDWILPsDyDHAEAEARHLVyEsDQNKDG |
| O43852 | Y47 | Sugiyama | CALU | RVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQLtPE |
| O60361 | Y136 | Sugiyama | NME2P1 | SLRFKPEELVDYKSCAHDWVyE___________________ |
| O60664 | Y95 | Sugiyama | PLIN3 M6PRBP1 TIP47 | VsGAQPILSKLEPQIAsAsEyAHRGLDKLEENLPILQQPTE |
| O60739 | Y30 | Sugiyama | EIF1B | FDPFADATKGDDLLPAGTEDyIHIRIQQRNGRKtLttVQGI |
| O60814 | Y43 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| O75347 | Y75 | Sugiyama | TBCA | EILQEsRMMIPDCQRRLEAAyLDLQRILENEKDLEEAEEyK |
| O75348 | Y47 | Sugiyama | ATP6V1G1 ATP6G ATP6G1 ATP6J | KRKNRRLKQAKEEAQAEIEQyRLQREKEFKAKEAAALGsRG |
| O75683 | Y10 | Sugiyama | SURF6 SURF-6 | ___________MASLLAKDAyLQsLAKKICSHsAPEQQART |
| O76087 | Y10 | Sugiyama | GAGE7 GAGE12I GAGE7B | ___________MSWRGRsTyyWPRPRRYVQPPEMIGPMRPE |
| O95218 | Y114 | Sugiyama | ZRANB2 ZIS ZNF265 | AKLEERtGYGGGFNERENVEyIEREEsDGEyDEFGRKKKKY |
| O95817 | T242 | Sugiyama | BAG3 BIS | QPsFHQAQKTHyPAQQGEyQtHQPVyHKIQGDDWEPRPLRA |
| P00558 | Y161 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | KAEPAKIEAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNL |
| P02786 | Y402 | Sugiyama | TFRC | KEIKILNIFGVIKGFVEPDHyVVVGAQRDAWGPGAAKSGVG |
| P04080 | Y97 | Sugiyama | CSTB CST6 STFB | NKPLtLsNyQTNKAKHDELtyF___________________ |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | Y314 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | tFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsK |
| P04406 | Y320 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE_____ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05362 | Y455 | Sugiyama | ICAM1 | GtFPLPIGEsVtVtRDLEGtyLCRARSTQGEVTRKVTVNVL |
| P06733 | S268 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | ASEFFRsGKyDLDFKsPDDPsRyIsPDQLADLyKsFIKDyP |
| P06733 | Y189 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | MILPVGAANFREAMRIGAEVyHNLKNVIKEKyGKDAtNVGD |
| P06733 | Y270 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | EFFRsGKyDLDFKsPDDPsRyIsPDQLADLyKsFIKDyPVV |
| P06733 | Y280 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | DFKsPDDPsRyIsPDQLADLyKsFIKDyPVVsIEDPFDQDD |
| P06733 | Y44 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | LFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKGVSK |
| P07205 | Y161 | Sugiyama | PGK2 PGKB | KAEPDKIEAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNL |
| P07437 | Y50 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | IDPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEP |
| P07437 | Y51 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | DPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEPG |
| P07711 | Y311 | Sugiyama | CTSL CTSL1 | DNNKYWLVKNsWGEEWGMGGyVKMAKDRRNHCGIAsAAsyP |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P07900 | Y492 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLR |
| P07900 | Y493 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | EMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLRK |
| P07900 | Y61 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | KEIFLRELIsNssDALDKIRyEsLtDPsKLDsGKELHINLI |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y472 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | sELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItGEsKE |
| P08238 | Y484 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVR |
| P08238 | Y485 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | EMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVRK |
| P08238 | Y56 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | KEIFLRELIsNAsDALDKIRyEsLtDPsKLDsGKELKIDII |
| P08238 | Y619 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | TANMERIMKAQALRDNstMGyMMAKKHLEINPDHPIVEtLR |
| P08708 | Y84 | Sugiyama | RPS17 RPS17L | GPVRGISIKLQEEERERRDNyVPEVsALDQEIIEVDPDtKE |
| P09234 | Y8 | Sugiyama | SNRPC | _____________MPKFyCDyCDtyLtHDsPsVRKTHCSGR |
| P0CG38 | Y1062 | Sugiyama | POTEI | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P0CG39 | Y1025 | Sugiyama | POTEJ | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P0CL80 | Y10 | Sugiyama | GAGE12F | ___________MSWRGRsTyyWPRPRRYVQPPEMIGPMRPE |
| P0DSO3 | Y10 | Sugiyama | GAGE4 | ___________MSWRGRsTyyWPRPRRYVQPPEMIGPMRPE |
| P10809 | Y223 | Sugiyama | HSPD1 HSP60 | DGKtLNDELEIIEGMKFDRGyIsPyFINtsKGQKCEFQDAy |
| P10809 | Y227 | Sugiyama | HSPD1 HSP60 | LNDELEIIEGMKFDRGyIsPyFINtsKGQKCEFQDAyVLLs |
| P10809 | Y243 | Sugiyama | HSPD1 HSP60 | yIsPyFINtsKGQKCEFQDAyVLLsEKKIssIQsIVPALEI |
| P11142 | Y134 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FYPEEVSSMVLTKMKEIAEAyLGKtVTNAVVtVPAyFNDsQ |
| P11142 | Y41 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P11142 | Y545 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | YKAEDEKQRDKVssKNsLEsyAFNMKATVEDEKLQGKINDE |
| P12277 | Y125 | Sugiyama | CKB CKBB | EHKTDLNPDNLQGGDDLDPNyVLssRVRTGRSIRGFCLPPH |
| P13073 | Y38 | Sugiyama | COX4I1 COX4 | SVCVRAHESVVKsEDFsLPAyMDRRDHPLPEVAHVKHLSAS |
| P13674 | Y282 | Sugiyama | P4HA1 P4HA | ASDDQSDQKTTPKKKGVAVDyLPERQKyEMLCRGEGIKMTP |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P13987 | Y86 | Sugiyama | CD59 MIC11 MIN1 MIN2 MIN3 MSK21 | KFEHCNFNDVtTRLRENELtyyCCKKDLCNFNEQLENGGTS |
| P14314 | Y106 | Sugiyama | PRKCSH G19P1 | yIPSNRVNDGVCDCCDGtDEyNsGVICENtCKEKGRKEREs |
| P14649 | Y86 | Sugiyama | MYL6B MLC1SA | LEEFKEAFELFDRVGDGKILysQCGDVMRALGQNPtNAEVL |
| P14854 | Y57 | Sugiyama | COX6B1 COX6B | FHRCQKAMTAKGGDIsVCEWyQRVYQsLCPtsWVTDWDEQR |
| P15328 | Y80 | Sugiyama | FOLR1 FOLR | WRKNACCSTNTSQEAHKDVsyLyRFNWNHCGEMAPACKRHF |
| P15880 | Y248 | Sugiyama | RPS2 RPS4 | GCtAtLGNFAKATFDAISKTysyLtPDLWKEtVFtKsPyQE |
| P15880 | Y250 | Sugiyama | RPS2 RPS4 | tAtLGNFAKATFDAISKTysyLtPDLWKEtVFtKsPyQEFt |
| P17066 | Y43 | Sugiyama | HSPA6 HSP70B' | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P17181 | Y466 | SIGNOR|ELM|iPTMNet|EPSD|PSP | IFNAR1 IFNAR | ALFALPFVIYAAKVFLRCINyVFFPSLKPsssIDEyFSEQP |
| P17181 | Y481 | SIGNOR|ELM|iPTMNet|EPSD|PSP | IFNAR1 IFNAR | LRCINyVFFPSLKPsssIDEyFSEQPLKNLLLstsEEQIEK |
| P17676 | Y139 | Sugiyama | CEBPB TCF5 PP9092 | SDLFSDDYGGKNCKKPAEyGyVsLGRLGAAKGALHPGCFAP |
| P18206 | Y822 | Sugiyama | VCL | KAVAGNIsDPGLQKsFLDsGyRILGAVAKVREAFQPQEPDF |
| P18615 | Y133 | Sugiyama | NELFE RD RDBP | sIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEA |
| P18615 | Y170 | Sugiyama | NELFE RD RDBP | GEEAEGPGAGDGPPRsFDWGyEERSGAHSsAsPPRsRSRDR |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P19105 | Y155 | Sugiyama | MYL12A MLCB MRLC3 RLC | DEEVDELyREAPIDKKGNFNyIEFtRILKHGAKDKDD____ |
| P19338 | Y462 | Sugiyama | NCL | AEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNSTWs |
| P20618 | Y158 | Sugiyama | PSMB1 PSC5 | IGGLDEEGKGAVysFDPVGsyQRDsFKAGGSASAMLQPLLD |
| P22234 | Y22 | Sugiyama | PAICS ADE2 AIRC PAIS | AtAEVLNIGKKLYEGKtKEVyELLDsPGKVLLQsKDQItAG |
| P22392 | Y151 | Sugiyama | NME2 NM23B | SLWFKPEELVDyKSCAHDWVyE___________________ |
| P23396 | Y34 | Sugiyama | RPS3 OK/SW-cl.26 | DGIFKAELNEFLtRELAEDGysGVEVRVtPTRTEIIILATR |
| P23528 | T70 | Sugiyama | CFL1 CFL | EEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyALyDAtyE |
| P23528 | Y140 | Sugiyama | CFL1 CFL | SKDAIKKKLtGIKHELQANCyEEVKDRCTLAEKLGGsAVIs |
| P24534 | Y18 | Sugiyama | EEF1B2 EEF1B EF1B | ___MGFGDLKsPAGLQVLNDyLADKSYIEGYVPsQADVAVF |
| P25398 | Y127 | Sugiyama | RPS12 | sCVVVKDYGKESQAKDVIEEyFKCKK_______________ |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P27348 | Y48 | Sugiyama | YWHAQ | AVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSIEQK |
| P27816 | Y47 | Sugiyama | MAP4 | AtLEAEAFDDVVGETVGKTDyIPLLDVDEKtGNsESKKKPC |
| P29353 | Y427 | Sugiyama | SHC1 SHC SHCA | RKQMPPPPPCPGRELFDDPsyVNVQNLDKARQAVGGAGPPN |
| P29597 | S1063 | Sugiyama | TYK2 | GLAKAVPEGHEyyRVREDGDsPVFWyAPECLKEYKFYYASD |
| P29597 | S912 | Sugiyama | TYK2 | FHKRYLKKIRDLGEGHFGKVsLyCyDPtNDGtGEMVAVKAL |
| P29597 | T919 | Sugiyama | TYK2 | KIRDLGEGHFGKVsLyCyDPtNDGtGEMVAVKALKADCGPQ |
| P29597 | T923 | Sugiyama | TYK2 | LGEGHFGKVsLyCyDPtNDGtGEMVAVKALKADCGPQHRSG |
| P29597 | Y1054 | SIGNOR|ELM|iPTMNet|EPSD|PSP|Sugiyama | TYK2 | DRLVKIGDFGLAKAVPEGHEyyRVREDGDsPVFWyAPECLK |
| P29597 | Y1055 | SIGNOR|ELM|iPTMNet|EPSD|PSP | TYK2 | RLVKIGDFGLAKAVPEGHEyyRVREDGDsPVFWyAPECLKE |
| P29597 | Y1068 | Sugiyama | TYK2 | VPEGHEyyRVREDGDsPVFWyAPECLKEYKFYYASDVWSFG |
| P29597 | Y1145 | Sugiyama | TYK2 | TELLERGERLPRPDKCPCEVyHLMKNCWETEASFRPTFENL |
| P29597 | Y292 | PSP | TYK2 | TERVPVCHLRLLAQAEGEPCyIRDSGVAPTDPGPESAAGPP |
| P29597 | Y914 | Sugiyama | TYK2 | KRYLKKIRDLGEGHFGKVsLyCyDPtNDGtGEMVAVKALKA |
| P29597 | Y916 | Sugiyama | TYK2 | YLKKIRDLGEGHFGKVsLyCyDPtNDGtGEMVAVKALKADC |
| P29597 | Y955 | Sugiyama | TYK2 | DCGPQHRSGWKQEIDILRTLyHEHIIKYKGCCEDQGEKSLQ |
| P29692 | Y26 | Sugiyama | EEF1D EF1D | LAHEKIWFDKFKYDDAERRFyEQMNGPVAGAsRQENGAsVI |
| P30086 | S104 | Sugiyama | PEBP1 PBP PEBP | WHHFLVVNMKGNDIssGtVLsDyVGsGPPKGtGLHRyVWLV |
| P30086 | Y106 | Sugiyama | PEBP1 PBP PEBP | HFLVVNMKGNDIssGtVLsDyVGsGPPKGtGLHRyVWLVyE |
| P30086 | Y176 | Sugiyama | PEBP1 PBP PEBP | KKyELRAPVAGtCyQAEWDDyVPKLyEQLsGK_________ |
| P30086 | Y64 | Sugiyama | PEBP1 PBP PEBP | tQVKNRPtsIsWDGLDsGKLytLVLtDPDAPsRKDPKYREW |
| P30101 | Y100 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | LAKVDCTANTNTCNKyGVsGyPtLKIFRDGEEAGAyDGPRt |
| P30101 | Y115 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | yGVsGyPtLKIFRDGEEAGAyDGPRtADGIVsHLKKQAGPA |
| P30101 | Y356 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | FVMQEEFsRDGKALERFLQDyFDGNLKRyLKsEPIPESNDG |
| P31943 | Y266 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | yNGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGstFQst |
| P31946 | Y50 | Sugiyama | YWHAB | AVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P31947 | Y48 | Sugiyama | SFN HME1 | GAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsIEQK |
| P31948 | Y354 | Sugiyama | STIP1 | DVLKKCQQAEKILKEQERLAyINPDLALEEKNKGNECFQKG |
| P31948 | Y41 | Sugiyama | STIP1 | DDALQCysEAIKLDPHNHVLysNRsAAyAKKGDYQKAyEDG |
| P32929 | Y60 | Sugiyama | CTH | PISLSTTFKQGAPGQHsGFEysRsGNPTRNCLEKAVAALDG |
| P32969 | Y180 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | LIQQATTVKNKDIRKFLDGIyVsEKGtVQQADE________ |
| P33316 | Y167 | Sugiyama | DUT | PPMEKAVVKTDIQIALPsGCyGRVAPRSGLAAKHFIDVGAG |
| P34931 | Y43 | Sugiyama | HSPA1L | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P37108 | Y27 | Sugiyama | SRP14 | EQFLtELTRLFQKCRTSGsVyItLKKYDGRTKPIPKKGtVE |
| P37802 | Y192 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NVIGLQMGtNRGAsQAGMtGyGMPRQIL_____________ |
| P38646 | Y196 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | EtAENyLGHtAKNAVItVPAyFNDsQRQAtKDAGQIsGLNV |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P40763 | Y640 | EPSD|PSP | STAT3 APRF | TFtWVEKDISGKTQIQSVEPyTKQQLNNMSFAEIIMGYKIM |
| P40818 | S719 | Sugiyama | USP8 KIAA0055 UBPY | KPQIPAERDREPSKLKRsyssPDItQAIQEEEKRKPTVtPT |
| P41567 | Y30 | Sugiyama | EIF1 SUI1 | FDPFADAsKGDDLLPAGTEDyIHIRIQQRNGRKtLttVQGI |
| P42224 | Y701 | GPS6|SIGNOR|iPTMNet|EPSD|PSP | STAT1 | YSRPKEAPEPMELDGPKGtGyIKtELIsVsEVHPSRLQttD |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46777 | Y207 | Sugiyama | RPL5 MSTP030 | sKEFNAEVHRKHIMGQNVADyMRyLMEEDEDAyKKQFsQyI |
| P46778 | Y30 | Sugiyama | RPL21 | GTRYMFSRPFRKHGVVPLAtyMRIYKKGDIVDIKGMGTVQK |
| P47224 | Y114 | Sugiyama | RABIF MSS4 RASGRF3 | CADCEIGPIGWHCLDDKNSFyVALERVSHE___________ |
| P47914 | Y98 | Sugiyama | RPL29 | PKEVKPKIPKGVSRKLDRLAyIAHPKLGKRARARIAKGLRL |
| P48741 | Y43 | Sugiyama | HSPA7 HSP70B | FQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAAL |
| P50990 | Y30 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | GFAQMLKEGAKHFsGLEEAVyRNIQACKELAQTTRTAYGPN |
| P51116 | Y614 | Sugiyama | FXR2 FMR1L2 | RGNRtDGsIsGDRQPVtVADyIsRAEsQsRQRPPLERTKPs |
| P51452 | Y138 | SIGNOR | DUSP3 VHR | GRVLVHCREGYSRSPTLVIAyLMMRQKMDVKSALSIVRQNR |
| P52597 | Y266 | Sugiyama | HNRNPF HNRPF | ySGLSDGYGFTTDLFGRDLsyCLsGMyDHRYGDsEFtVQsT |
| P53634 | Y438 | Sugiyama | CTSC CPPI | SGMDYWIVKNsWGtGWGENGyFRIRRGtDECAIEsIAVAAt |
| P54652 | Y42 | Sugiyama | HSPA2 | FQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVAM |
| P55795 | Y266 | Sugiyama | HNRNPH2 FTP3 HNRPH2 | YGGYNDGYGFGSDRFGRDLNyCFsGMsDHRyGDGGssFQst |
| P57053 | Y43 | Sugiyama | H2BC12L H2BFS H2BS1 | QKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| P58876 | Y43 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| P60174 | Y209 | Sugiyama | TPI1 TPI | LRGWLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDG |
| P60660 | Y29 | Sugiyama | MYL6 | TAEFKEAFQLFDRtGDGKILysQCGDVMRALGQNPtNAEVL |
| P60660 | Y89 | Sugiyama | MYL6 | HFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMGAEI |
| P60709 | Y198 | Sugiyama | ACTB | LDLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCy |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P60709 | Y362 | Sugiyama | ACTB | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P61024 | Y7 | Sugiyama | CKS1B CKS1 PNAS-143 PNAS-16 | ______________MSHKQIyysDKyDDEEFEyRHVMLPKD |
| P61081 | Y172 | Sugiyama | UBE2M UBC12 | VLQNNRRLFEQNVQRSMRGGyIGstyFERCLK_________ |
| P61081 | Y177 | Sugiyama | UBE2M UBC12 | RRLFEQNVQRSMRGGyIGstyFERCLK______________ |
| P61247 | Y256 | Sugiyama | RPS3A FTE1 MFTL | sssGKAtGDEtGAKVERADGyEPPVQEsV____________ |
| P61247 | Y31 | Sugiyama | RPS3A FTE1 MFTL | KGGKKGAKKKVVDPFSKKDWyDVKAPAMFNIRNIGKTLVTR |
| P61604 | T79 | Sugiyama | HSPE1 | EIQPVsVKVGDKVLLPEyGGtKVVLDDKDyFLFRDGDILGK |
| P61604 | Y76 | Sugiyama | HSPE1 | KGGEIQPVsVKVGDKVLLPEyGGtKVVLDDKDyFLFRDGDI |
| P61978 | Y323 | Sugiyama | HNRNPK HNRPK | RARNLPLPPPPPPRGGDLMAyDRRGRPGDRYDGMVGFSADE |
| P61981 | Y49 | Sugiyama | YWHAG | NVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSIEQK |
| P62081 | Y177 | Sugiyama | RPS7 | HLDKAQQNNVEHKVEtFsGVyKKLTGKDVNFEFPEFQL___ |
| P62258 | Y49 | Sugiyama | YWHAE | KVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssIEQK |
| P62269 | S96 | Sugiyama | RPS18 D6S218E | QYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLKK |
| P62269 | Y95 | Sugiyama | RPS18 D6S218E | RQYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLK |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | Y18 | Sugiyama | RPS13 | ___MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVKEQIy |
| P62280 | Y55 | Sugiyama | RPS11 | RYYKNIGLGFKtPKEAIEGtyIDKKCPFTGNVsIRGRILsG |
| P62312 | Y72 | Sugiyama | LSM6 | VNGQLKNKyGDAFIRGNNVLyIstQKRRM____________ |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P62750 | Y144 | Sugiyama | RPL23A | VNtLIRPDGEKKAYVRLAPDyDALDVANKIGII________ |
| P62753 | Y156 | Sugiyama | RPS6 OK/SW-cl.2 | KRASRIRKLFNLsKEDDVRQyVVRKPLNKEGKKPRTKAPKI |
| P62807 | Y43 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | QKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| P62826 | Y146 | Sugiyama | RAN ARA24 OK/SW-cl.81 | IKDRKVKAKsIVFHRKKNLQyyDIsAKSNyNFEKPFLWLAR |
| P62826 | Y147 | Sugiyama | RAN ARA24 OK/SW-cl.81 | KDRKVKAKsIVFHRKKNLQyyDIsAKSNyNFEKPFLWLARK |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P62979 | Y148 | Sugiyama | RPS27A UBA80 UBCEP1 | AGVFMAsHFDRHyCGKCCLtyCFNKPEDK____________ |
| P63104 | Y48 | Sugiyama | YWHAZ | sVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssIEQK |
| P63220 | T52 | Sugiyama | RPS21 | IQMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRL |
| P63220 | Y53 | Sugiyama | RPS21 | QMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRLA |
| P63244 | Y194 | ELM|iPTMNet|EPSD|PSP | RACK1 GNB2L1 HLC7 PIG21 | VKVWNLANCKLKTNHIGHtGyLNTVTVSPDGSLCASGGKDG |
| P63261 | Y198 | Sugiyama | ACTG1 ACTG | LDLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCy |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63261 | Y362 | Sugiyama | ACTG1 ACTG | GGsILAsLstFQQMWISKQEyDEsGPsIVHRKCF_______ |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68104 | Y29 | Sugiyama | EEF1A1 EEF1A EF1A LENG7 | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| P83731 | Y11 | Sugiyama | RPL24 | __________MKVELCsFsGyKIYPGHGRRYARTDGKVFQF |
| P84103 | Y33 | Sugiyama | SRSF3 SFRS3 SRP20 | yVGNLGNNGNKtELERAFGyyGPLRSVWVARNPPGFAFVEF |
| P98082 | Y38 | Sugiyama | DAB2 DOC2 | AAPKAPsKKEKKKGPEKTDEyLLARFKGDGVKYKAKLIGID |
| P98179 | Y127 | Sugiyama | RBM3 RNPL | GGDQGYGSGRyyDsRPGGyGyGyGRSRDYNGRNQGGYDRys |
| P98179 | Y129 | Sugiyama | RBM3 RNPL | DQGYGSGRyyDsRPGGyGyGyGRSRDYNGRNQGGYDRysGG |
| Q00839 | Y257 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | QKGGDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVE |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q01105 | Y146 | Sugiyama | SET | tEFEDIKsGyRIDFyFDENPyFENKVLSKEFHLNEsGDPss |
| Q01130 | Y44 | Sugiyama | SRSF2 SFRS2 | RtsPDtLRRVFEKYGRVGDVyIPRDRYTKESRGFAFVRFHD |
| Q04917 | Y49 | Sugiyama | YWHAH YWHA1 | AVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSIEQK |
| Q05639 | Y29 | Sugiyama | EEF1A2 EEF1AL STN | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q13069 | Y10 | Sugiyama | GAGE5 | ___________MSWRGRsTyyWPRPRRYVQPPEVIGPMRPE |
| Q13070 | Y10 | Sugiyama | GAGE6 | ___________MSWRGRsTyyWPRPRRYVQPPEVIGPMRPE |
| Q13303 | Y270 | Sugiyama | KCNAB2 KCNA2B KCNK2 | IVSGKYDSGIPPYSRAsLKGyQWLKDKILSEEGRRQQAKLK |
| Q13442 | T18 | Sugiyama | PDAP1 HASPP28 | ___MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEE |
| Q13573 | Y176 | Sugiyama | SNW1 SKIIP SKIP | SQKVAAAMPVRAADKLAPAQyIRytPsQQGVAFNsGAKQRV |
| Q13573 | Y260 | Sugiyama | SNW1 SKIIP SKIP | KEQQEWKIPPCISNWKNAKGytIPLDKRLAADGRGLQTVHI |
| Q13651 | Y446 | GPS6|ELM|iPTMNet|EPSD | IL10RA IL10R | SPPEPEVPGEEDPAAVAFQGyLRQTRCAEEKATKTGCLEEE |
| Q13651 | Y496 | GPS6|ELM|iPTMNet|EPSD | IL10RA IL10R | KFGRCLVDEAGLHPPALAKGyLKQDPLEMTLASSGAPTGQW |
| Q13765 | S117 | Sugiyama | NACA HSD48 | RKSKNILFVITKPDVYKSPAsDtyIVFGEAKIEDLsQQAQL |
| Q13765 | Y120 | Sugiyama | NACA HSD48 | KNILFVITKPDVYKSPAsDtyIVFGEAKIEDLsQQAQLAAA |
| Q14247 | Y334 | Sugiyama | CTTN EMS1 | KDRMDKNAstFEDVtQVssAyQKTVPVEAVtsKtsNIRANF |
| Q14257 | Y311 | Sugiyama | RCN2 ERC55 | NPDLFLtsEAtDyGRQLHDDyFyHDEL______________ |
| Q14257 | Y313 | Sugiyama | RCN2 ERC55 | DLFLtsEAtDyGRQLHDDyFyHDEL________________ |
| Q14671 | Y83 | Sugiyama | PUM1 KIAA0099 PUMH1 | SPVPGSIGVAGRsQDDAMVDyFFQRQHGEQLGGGGsGGGGy |
| Q15293 | Y278 | Sugiyama | RCN1 RCN | LNKDGKLDKDEIRHWILPQDyDHAQAEARHLVyESDKNKDE |
| Q15424 | Y723 | Sugiyama | SAFB HAP HET SAFB1 | EQERRPAVRRPYDLDRRDDAyWPEAKRAALDERYHSDFNRQ |
| Q15427 | Y16 | Sugiyama | SF3B4 SAP49 | _____MAAGPISERNQDAtVyVGGLDEKVSEPLLWELFLQA |
| Q15527 | Y123 | Sugiyama | SURF2 | GRRYQRALCKYEECQKQGVEyVPACLVHRRRRREDQMDGDG |
| Q15555 | Y268 | Sugiyama | MAPRE2 RP1 | NEQVHsLKLALEGVEKERDFyFGKLREIELLCQEHGQENDD |
| Q15691 | Y217 | Sugiyama | MAPRE1 | MQQVNVLKLtVEDLEKERDFyFGKLRNIELICQENEGENDP |
| Q16719 | S443 | Sugiyama | KYNU | VVCDKRNPNGIRVAPVPLyNsFHDVyKFTNLLtsILDsAET |
| Q16719 | Y448 | Sugiyama | KYNU | RNPNGIRVAPVPLyNsFHDVyKFTNLLtsILDsAETKN___ |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q58FF6 | Y32 | Sugiyama | HSP90AB4P | KEIFLQELISNASDALDKIRyEsLtDPsKLDGGKELKIDII |
| Q58FF7 | Y492 | Sugiyama | HSP90AB3P HSP90BC | TANMEQIMKAQALRDNstMGyMMAKKHLEINPDHPIMETLR |
| Q58FF7 | Y56 | Sugiyama | HSP90AB3P HSP90BC | EEIFLQELISNASDALDKIRyEsLtDPsKLDsGKELKIDII |
| Q58FF8 | Y260 | Sugiyama | HSP90AB2P HSP90BB | VRYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVW |
| Q58FF8 | Y261 | Sugiyama | HSP90AB2P HSP90BB | RYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVWK |
| Q58FF8 | Y56 | Sugiyama | HSP90AB2P HSP90BB | KEIFLWELISNASDALDKIRyEsLtDPsKLDsGKELKIDII |
| Q58FG0 | Y177 | Sugiyama | HSP90AA5P HSP90AE | GQLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQ |
| Q58FG0 | Y178 | Sugiyama | HSP90AA5P HSP90AE | QLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQK |
| Q5JTH9 | Y1251 | Sugiyama | RRP12 KIAA0690 | AEYKAKKAKGDVKKKGRPDPyAyIPLNRSKLNRRKKMKLQG |
| Q5JTH9 | Y1253 | Sugiyama | RRP12 KIAA0690 | YKAKKAKGDVKKKGRPDPyAyIPLNRSKLNRRKKMKLQGQF |
| Q5QNW6 | Y43 | Sugiyama | H2BC18 HIST2H2BF | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| Q5VTE0 | Y29 | Sugiyama | EEF1A1P5 EEF1AL3 | NIVVIGHVDsGKstttGHLIyKCGGIDKRTIEKFEKEAAEM |
| Q6FI81 | Y278 | Sugiyama | CIAPIN1 CUA001 PRO0915 | EKEKSREQMSSQPKsACGNCyLGDAFRCAsCPyLGMPAFKP |
| Q6S8J3 | Y1062 | Sugiyama | POTEE A26C1A POTE2 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q6UN15 | Y453 | Sugiyama | FIP1L1 FIP1 RHE | HLPGSAPsWPSLVDTSKQWDyyARREKDRDRERDRDRERDR |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q86V81 | Y250 | Sugiyama | ALYREF ALY BEF THOC4 | AGRNSKQQLsAEELDAQLDAyNARMDts_____________ |
| Q8N6H7 | Y278 | Sugiyama | ARFGAP2 ZNF289 Nbla10535 | QAADAKKQAEESMVASMRLAyQELQIDRKKEEKKLQNLEGK |
| Q8ND56 | Y455 | Sugiyama | LSM14A C19orf13 FAM61A RAP55 RAP55A | RGFRGGFRGGRGGREFADFEyRKTTAFGP____________ |
| Q8NI22 | Y135 | Sugiyama | MCFD2 SDNSF | DELINIIDGVLRDDDKNNDGyIDyAEFAKSLQ_________ |
| Q8TDD1 | Y681 | Sugiyama | DDX54 | GPNRGAKRRREEARQRDQEFyIPyRPKDFDSERGLsIsGEG |
| Q92882 | Y207 | Sugiyama | OSTF1 | sLLKKKQGTDAVRtLsNAEDyLDDEDsD_____________ |
| Q93079 | Y43 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| Q96CT7 | Y38 | Sugiyama | CCDC124 | RRAEAKAAADAKKQKELEDAyWKDDDKHVMRKEQRKEEKEK |
| Q99470 | Y69 | Sugiyama | SDF2 | GSGSGQQSVTGVTSVDDSNSyWRIRGKSATVCERGTPIKCG |
| Q99877 | Y43 | Sugiyama | H2BC15 H2BFD HIST1H2BN | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| Q99879 | Y43 | Sugiyama | H2BC14 H2BFE HIST1H2BM | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| Q99880 | Y43 | Sugiyama | H2BC13 H2BFC HIST1H2BL | QKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKAMGIM |
| Q99961 | Y57 | Sugiyama | SH3GL1 CNSA1 SH3D2B | EKKVDVTSKAVTEVLARTIEyLQPNPAsRAKLTMLNTVSKI |
| Q99962 | Y57 | Sugiyama | SH3GL2 CNSA2 SH3D2A | ERKVDVTSRAVMEIMTKTIEyLQPNPAsRAKLSMINTMsKI |
| Q9BQE3 | Y432 | Sugiyama | TUBA1C TUBA6 | GMEEGEFSEAREDMAALEKDyEEVGADsADGEDEGEEy___ |
| Q9BRL6 | Y44 | Sugiyama | SRSF8 SFRS2B SRP46 | RtsPDsLRRVFEKYGRVGDVyIPREPHTKAPRGFAFVRFHD |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9BYX7 | Y362 | Sugiyama | POTEKP ACTBL3 FKSG30 | GGSILASLSTFQQMWISKQEyDEsGPsIVHRKCF_______ |
| Q9HAP6 | Y118 | Sugiyama | LIN7B MALS2 VELI2 UNQ3116/PRO10200 | KTDEGLGFNIMGGKEQNsPIyIsRVIPGGVADRHGGLKRGD |
| Q9HCN8 | Y81 | Sugiyama | SDF2L1 UNQ1941/PRO4424 | GSGSGQQSVtGVEAsDDANSyWRIRGGSEGGCPRGSPVRCG |
| Q9HDC5 | Y417 | Sugiyama | JPH1 JP1 | AARQECDIARAVARELsPDFyQPGPDyVKQRFQEGVDAKEN |
| Q9HDC5 | Y423 | Sugiyama | JPH1 JP1 | DIARAVARELsPDFyQPGPDyVKQRFQEGVDAKENPEEKVP |
| Q9NP61 | Y432 | Sugiyama | ARFGAP3 ARFGAP1 | ENTDEAQKKFGNVKAIssDMyFGRQsQADYETRARLERLsA |
| Q9NRX4 | Y116 | Sugiyama | PHPT1 PHP14 CGI-202 HSPC141 | AyGPAQHAISTEKIKAKyPDyEVtWANDGy___________ |
| Q9NUP9 | Y118 | Sugiyama | LIN7C MALS3 VELI3 | KTEEGLGFNIMGGKEQNsPIyIsRIIPGGIADRHGGLKRGD |
| Q9NVS9 | Y157 | Sugiyama | PNPO | NRQVRVEGPVKKLPEEEAECyFHSRPKssQIGAVVSHQSSV |
| Q9NVS9 | Y256 | Sugiyama | PNPO | LPtGDsPLGPMTHRGEEDWLyERLAP_______________ |
| Q9UBR2 | Y76 | Sugiyama | CTSZ | YLSPADLPKSWDWRNVDGVNyAsItRNQHIPQYCGSCWAHA |
| Q9UI15 | Y192 | Sugiyama | TAGLN3 NP25 | NVIGLQMGSNKGAsQAGMtGyGMPRQIM_____________ |
| Q9UII2 | Y58 | Sugiyama | ATP5IF1 ATPI ATPIF1 | GsIREAGGAFGKREQAEEERyFRAQsREQLAALKKHHEEEI |
| Q9UMX5 | Y65 | Sugiyama | NENF CIR2 SPUF | RLFtEEELARYGGEEEDQPIyLAVKGVVFDVtSGKEFYGRG |
| Q9UN86 | Y19 | Sugiyama | G3BP2 KIAA0660 | __MVMEKPsPLLVGREFVRQyytLLNKAPEYLHRFYGRNSS |
| Q9Y2B0 | Y71 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | IQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEICDRMKE |
| Q9Y2W1 | T230 | Sugiyama | THRAP3 BCLAF2 TRAP150 | tsQDTKAsEssKPWPDAtyGtGsAsRAsAVsELsPRERsPA |
| Q9Y2W1 | Y228 | Sugiyama | THRAP3 BCLAF2 TRAP150 | GGtsQDTKAsEssKPWPDAtyGtGsAsRAsAVsELsPRERs |
| Q9Y3U8 | Y53 | Sugiyama | RPL36 | LTKHTKFVRDMIREVCGFAPyERRAMELLKVSKDKRALKFI |
| Q9Y5Y0 | Y22 | Sugiyama | FLVCR1 FLVCR | ARPDDEEGAAVAPGHPLAKGyLPLPRGAPVGKESVELQNGP |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.509903e-14 | 13.821 | 1 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.376910e-11 | 10.471 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.125051e-07 | 6.505 | 1 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 7.043381e-07 | 6.152 | 1 | 1 |
| Signaling by ALK in cancer | R-HSA-9700206 | 7.043381e-07 | 6.152 | 1 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.483830e-06 | 5.829 | 1 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.156452e-06 | 5.666 | 1 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 4.406486e-06 | 5.356 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 5.846101e-06 | 5.233 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 6.223175e-06 | 5.206 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 9.436834e-06 | 5.025 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.396351e-05 | 4.855 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 1.036062e-05 | 4.985 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 1.359274e-05 | 4.867 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.483950e-05 | 4.829 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.396351e-05 | 4.855 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.346777e-05 | 4.871 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.589260e-05 | 4.799 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.753452e-05 | 4.756 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.799674e-05 | 4.745 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.792272e-05 | 4.554 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 2.933790e-05 | 4.533 | 1 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 3.332722e-05 | 4.477 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 3.093809e-05 | 4.510 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 3.515936e-05 | 4.454 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 3.530292e-05 | 4.452 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.015582e-05 | 4.396 | 1 | 1 |
| PI3K Cascade | R-HSA-109704 | 4.043114e-05 | 4.393 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 4.521850e-05 | 4.345 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 4.452689e-05 | 4.351 | 1 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.539035e-05 | 4.123 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.050305e-04 | 3.979 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 1.310830e-04 | 3.882 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.215779e-04 | 3.915 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.215779e-04 | 3.915 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.309675e-04 | 3.883 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.360557e-04 | 3.866 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.374058e-04 | 3.862 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.588827e-04 | 3.799 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.782680e-04 | 3.749 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.126495e-04 | 3.672 | 1 | 1 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.303772e-04 | 3.638 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.784189e-04 | 3.555 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 3.162584e-04 | 3.500 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 3.826704e-04 | 3.417 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.027736e-04 | 3.395 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.826704e-04 | 3.417 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.826704e-04 | 3.417 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.886947e-04 | 3.311 | 1 | 1 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.886947e-04 | 3.311 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.742667e-04 | 3.324 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 5.624680e-04 | 3.250 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 5.334565e-04 | 3.273 | 1 | 0 |
| Immune System | R-HSA-168256 | 5.620137e-04 | 3.250 | 1 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 6.244429e-04 | 3.205 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 6.244429e-04 | 3.205 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 7.145735e-04 | 3.146 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.181542e-04 | 3.087 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.393041e-04 | 3.076 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.140624e-03 | 2.943 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.140624e-03 | 2.943 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.061257e-03 | 2.974 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 1.337704e-03 | 2.874 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.337704e-03 | 2.874 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 1.337704e-03 | 2.874 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.320156e-03 | 2.879 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.241303e-03 | 2.906 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 1.516521e-03 | 2.819 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.534434e-03 | 2.814 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.730276e-03 | 2.762 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.961957e-03 | 2.707 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.961957e-03 | 2.707 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.068054e-03 | 2.684 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 1.913003e-03 | 2.718 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.008925e-03 | 2.697 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.073399e-03 | 2.683 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.212075e-03 | 2.655 | 1 | 1 |
| Hemostasis | R-HSA-109582 | 2.279582e-03 | 2.642 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.386527e-03 | 2.622 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.516804e-03 | 2.599 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 2.554661e-03 | 2.593 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.585860e-03 | 2.587 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.107559e-03 | 2.508 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.077855e-03 | 2.512 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 3.406417e-03 | 2.468 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 3.406417e-03 | 2.468 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 3.755660e-03 | 2.425 | 1 | 1 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.755660e-03 | 2.425 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 4.215923e-03 | 2.375 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 4.125973e-03 | 2.384 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.125973e-03 | 2.384 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.371928e-03 | 2.359 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 4.517723e-03 | 2.345 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.517723e-03 | 2.345 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.517723e-03 | 2.345 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.969045e-03 | 2.304 | 0 | 0 |
| Disease | R-HSA-1643685 | 5.011986e-03 | 2.300 | 1 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 5.169051e-03 | 2.287 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.366922e-03 | 2.270 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.305847e-03 | 2.200 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.211578e-03 | 2.207 | 1 | 1 |
| Signaling by FGFR | R-HSA-190236 | 6.313646e-03 | 2.200 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 6.809688e-03 | 2.167 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 6.809688e-03 | 2.167 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.336806e-03 | 2.134 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.336806e-03 | 2.134 | 1 | 1 |
| ALK mutants bind TKIs | R-HSA-9700645 | 7.341542e-03 | 2.134 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 7.887448e-03 | 2.103 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 8.461846e-03 | 2.073 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.557015e-03 | 2.068 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 8.557015e-03 | 2.068 | 1 | 1 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 8.557015e-03 | 2.068 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 8.557015e-03 | 2.068 | 1 | 1 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 1.032966e-02 | 1.986 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.032966e-02 | 1.986 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.100110e-02 | 1.959 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.100110e-02 | 1.959 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 1.123692e-02 | 1.949 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.169723e-02 | 1.932 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.269764e-02 | 1.896 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.269764e-02 | 1.896 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.269764e-02 | 1.896 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.423646e-02 | 1.847 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.423646e-02 | 1.847 | 1 | 1 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.269764e-02 | 1.896 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.269764e-02 | 1.896 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.269764e-02 | 1.896 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.393515e-02 | 1.856 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.393515e-02 | 1.856 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.393515e-02 | 1.856 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.269764e-02 | 1.896 | 1 | 1 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.423646e-02 | 1.847 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 1.241820e-02 | 1.906 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.357178e-02 | 1.867 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.464238e-02 | 1.834 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 1.555287e-02 | 1.808 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.585158e-02 | 1.800 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 1.585158e-02 | 1.800 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.727908e-02 | 1.762 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 1.754127e-02 | 1.756 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.754127e-02 | 1.756 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.754127e-02 | 1.756 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.754127e-02 | 1.756 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.754127e-02 | 1.756 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.754127e-02 | 1.756 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.816986e-02 | 1.741 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.816986e-02 | 1.741 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.930378e-02 | 1.714 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.113743e-02 | 1.675 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 2.304054e-02 | 1.638 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.004216e-02 | 1.698 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.304054e-02 | 1.638 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.304054e-02 | 1.638 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 1.930378e-02 | 1.714 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.930378e-02 | 1.714 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.101671e-02 | 1.677 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.089402e-02 | 1.680 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.945227e-02 | 1.711 | 1 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.304054e-02 | 1.638 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 2.113743e-02 | 1.675 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.113743e-02 | 1.675 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.363162e-02 | 1.627 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 2.437703e-02 | 1.613 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.501148e-02 | 1.602 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 2.501148e-02 | 1.602 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.627391e-02 | 1.580 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.630159e-02 | 1.580 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.630159e-02 | 1.580 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.630159e-02 | 1.580 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.704862e-02 | 1.568 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.714310e-02 | 1.566 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 2.750027e-02 | 1.561 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.812341e-02 | 1.551 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 2.855593e-02 | 1.544 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 3.117770e-02 | 1.506 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 3.117770e-02 | 1.506 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 3.117770e-02 | 1.506 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.582782e-02 | 1.446 | 1 | 1 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.093987e-02 | 1.509 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.131519e-02 | 1.504 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.131519e-02 | 1.504 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.342528e-02 | 1.476 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.093987e-02 | 1.509 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.354151e-02 | 1.474 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 2.915038e-02 | 1.535 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.117770e-02 | 1.506 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.131519e-02 | 1.504 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.582782e-02 | 1.446 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 3.869799e-02 | 1.412 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 3.582782e-02 | 1.446 | 1 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 3.734230e-02 | 1.428 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.869799e-02 | 1.412 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.354151e-02 | 1.474 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.915038e-02 | 1.535 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 2.973518e-02 | 1.527 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.371200e-02 | 1.472 | 1 | 1 |
| Signaling by PDGF | R-HSA-186797 | 3.869799e-02 | 1.412 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.443476e-02 | 1.463 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 3.093987e-02 | 1.509 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.007852e-02 | 1.397 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.057451e-02 | 1.392 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 4.057451e-02 | 1.392 | 1 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.057451e-02 | 1.392 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 4.135400e-02 | 1.383 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 4.135400e-02 | 1.383 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) | R-HSA-5619049 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 4.135400e-02 | 1.383 | 0 | 0 |
| Defective ADA disrupts (deoxy)adenosine deamination | R-HSA-9734735 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 4.135400e-02 | 1.383 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 4.135400e-02 | 1.383 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 4.135400e-02 | 1.383 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 4.135400e-02 | 1.383 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 4.135400e-02 | 1.383 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.147345e-02 | 1.382 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.548670e-02 | 1.342 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 4.554362e-02 | 1.342 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.554362e-02 | 1.342 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.142402e-02 | 1.289 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.142402e-02 | 1.289 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 5.142402e-02 | 1.289 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.142402e-02 | 1.289 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 6.138889e-02 | 1.212 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 6.138889e-02 | 1.212 | 0 | 0 |
| Defective CP causes aceruloplasminemia (ACERULOP) | R-HSA-5619060 | 6.138889e-02 | 1.212 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 6.138889e-02 | 1.212 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 7.124968e-02 | 1.147 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 7.124968e-02 | 1.147 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 7.124968e-02 | 1.147 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.338983e-02 | 1.273 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.610450e-02 | 1.251 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 6.721824e-02 | 1.173 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.886660e-02 | 1.230 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 6.452802e-02 | 1.190 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 6.167486e-02 | 1.210 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 7.124968e-02 | 1.147 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 7.124968e-02 | 1.147 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 6.367787e-02 | 1.196 | 1 | 1 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 4.810805e-02 | 1.318 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 5.142402e-02 | 1.289 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.522252e-02 | 1.258 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 6.721824e-02 | 1.173 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 6.452802e-02 | 1.190 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 4.810805e-02 | 1.318 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 5.072391e-02 | 1.295 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.338983e-02 | 1.273 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.036407e-02 | 1.153 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.810805e-02 | 1.318 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 5.886660e-02 | 1.230 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 6.138889e-02 | 1.212 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 6.138889e-02 | 1.212 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 6.138889e-02 | 1.212 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 7.124968e-02 | 1.147 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 7.124968e-02 | 1.147 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 7.124968e-02 | 1.147 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 6.742483e-02 | 1.171 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.022719e-02 | 1.220 | 1 | 1 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 7.084679e-02 | 1.150 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 4.994250e-02 | 1.302 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 7.124968e-02 | 1.147 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 5.597492e-02 | 1.252 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 5.853594e-02 | 1.233 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.686766e-02 | 1.245 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 6.452802e-02 | 1.190 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 6.452802e-02 | 1.190 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 7.636510e-02 | 1.117 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 7.636510e-02 | 1.117 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 7.636510e-02 | 1.117 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 7.636510e-02 | 1.117 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 7.654870e-02 | 1.116 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 8.100748e-02 | 1.091 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 8.100748e-02 | 1.091 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.100748e-02 | 1.091 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 8.100748e-02 | 1.091 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 8.100748e-02 | 1.091 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 8.100748e-02 | 1.091 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 9.066336e-02 | 1.043 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 9.066336e-02 | 1.043 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 9.066336e-02 | 1.043 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 9.066336e-02 | 1.043 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 1.096736e-01 | 0.960 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 1.096736e-01 | 0.960 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 1.096736e-01 | 0.960 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.096736e-01 | 0.960 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.096736e-01 | 0.960 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 1.190300e-01 | 0.924 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.190300e-01 | 0.924 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.282887e-01 | 0.892 | 0 | 0 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | R-HSA-629594 | 1.282887e-01 | 0.892 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 1.282887e-01 | 0.892 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.374506e-01 | 0.862 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.374506e-01 | 0.862 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.374506e-01 | 0.862 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.465168e-01 | 0.834 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.554882e-01 | 0.808 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.554882e-01 | 0.808 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.554882e-01 | 0.808 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.554882e-01 | 0.808 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.554882e-01 | 0.808 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 1.618330e-01 | 0.791 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 9.009716e-02 | 1.045 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.471637e-01 | 0.832 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.465168e-01 | 0.834 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 1.002184e-01 | 0.999 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.282887e-01 | 0.892 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.374506e-01 | 0.862 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.370930e-01 | 0.863 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 8.100748e-02 | 1.091 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.859025e-02 | 1.006 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.592659e-01 | 0.798 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.592659e-01 | 0.798 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 8.100748e-02 | 1.091 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 8.100748e-02 | 1.091 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 8.100748e-02 | 1.091 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.374506e-01 | 0.862 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 1.374506e-01 | 0.862 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.374506e-01 | 0.862 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.465168e-01 | 0.834 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.465168e-01 | 0.834 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.465168e-01 | 0.834 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.554882e-01 | 0.808 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 8.882500e-02 | 1.051 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.754632e-02 | 1.058 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.508049e-01 | 0.822 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.071989e-01 | 0.970 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 8.100748e-02 | 1.091 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.002184e-01 | 0.999 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 1.190300e-01 | 0.924 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.554882e-01 | 0.808 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.554882e-01 | 0.808 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.435412e-01 | 0.843 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.581403e-01 | 0.801 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.018366e-01 | 0.992 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 1.096736e-01 | 0.960 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.085285e-01 | 0.964 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.206985e-01 | 0.918 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 8.100748e-02 | 1.091 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 1.002184e-01 | 0.999 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 1.096736e-01 | 0.960 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.190300e-01 | 0.924 | 1 | 1 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.465168e-01 | 0.834 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.346992e-01 | 0.871 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.346992e-01 | 0.871 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.171608e-01 | 0.931 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 9.066336e-02 | 1.043 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.554882e-01 | 0.808 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.554882e-01 | 0.808 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 9.202885e-02 | 1.036 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 9.202885e-02 | 1.036 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 9.202885e-02 | 1.036 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 8.100748e-02 | 1.091 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 9.066336e-02 | 1.043 | 0 | 0 |
| RSK activation | R-HSA-444257 | 1.096736e-01 | 0.960 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.190300e-01 | 0.924 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.282887e-01 | 0.892 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 1.465168e-01 | 0.834 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 1.554882e-01 | 0.808 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 1.257378e-01 | 0.901 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.618330e-01 | 0.791 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.564770e-01 | 0.806 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.100748e-02 | 1.091 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 8.100748e-02 | 1.091 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 8.100748e-02 | 1.091 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 1.096736e-01 | 0.960 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.554882e-01 | 0.808 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.554882e-01 | 0.808 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.554882e-01 | 0.808 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.222448e-01 | 0.913 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.618330e-01 | 0.791 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.584809e-01 | 0.800 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 9.526610e-02 | 1.021 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.190300e-01 | 0.924 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 9.853571e-02 | 1.006 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.646913e-02 | 1.016 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.090121e-01 | 0.963 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.326968e-02 | 1.030 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.603859e-01 | 0.795 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 9.202885e-02 | 1.036 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 9.742778e-02 | 1.011 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.190300e-01 | 0.924 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.229573e-01 | 0.910 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 9.693803e-02 | 1.014 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.116163e-01 | 0.952 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 1.618330e-01 | 0.791 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.466998e-01 | 0.834 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.466998e-01 | 0.834 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.374982e-01 | 0.862 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 1.327940e-01 | 0.877 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.428584e-01 | 0.845 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 1.508049e-01 | 0.822 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 1.252745e-01 | 0.902 | 1 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 8.565560e-02 | 1.067 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.222448e-01 | 0.913 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.618330e-01 | 0.791 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 1.618330e-01 | 0.791 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 1.618330e-01 | 0.791 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 1.618330e-01 | 0.791 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 1.618330e-01 | 0.791 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 1.618330e-01 | 0.791 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.106256e-01 | 0.956 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.051679e-01 | 0.978 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.422737e-01 | 0.847 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.442100e-01 | 0.841 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.147446e-02 | 1.089 | 1 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.621388e-02 | 1.064 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 1.618330e-01 | 0.791 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 1.643659e-01 | 0.784 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.643659e-01 | 0.784 | 1 | 1 |
| Processing of SMDT1 | R-HSA-8949664 | 1.643659e-01 | 0.784 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 1.643659e-01 | 0.784 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.643659e-01 | 0.784 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 1.643659e-01 | 0.784 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.643659e-01 | 0.784 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 1.643659e-01 | 0.784 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.643659e-01 | 0.784 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.668893e-01 | 0.778 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.700435e-01 | 0.769 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.720306e-01 | 0.764 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 1.730020e-01 | 0.762 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.731508e-01 | 0.762 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.731508e-01 | 0.762 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.731508e-01 | 0.762 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 1.731508e-01 | 0.762 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.731508e-01 | 0.762 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 1.767530e-01 | 0.753 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.798263e-01 | 0.745 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.805168e-01 | 0.743 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.818439e-01 | 0.740 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.818439e-01 | 0.740 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.818439e-01 | 0.740 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.818439e-01 | 0.740 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 1.818439e-01 | 0.740 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 1.818439e-01 | 0.740 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 1.818439e-01 | 0.740 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.818439e-01 | 0.740 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.840704e-01 | 0.735 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.850766e-01 | 0.733 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.871761e-01 | 0.728 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 1.877169e-01 | 0.726 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.903671e-01 | 0.720 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.904462e-01 | 0.720 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.935390e-01 | 0.713 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.989585e-01 | 0.701 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.989585e-01 | 0.701 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.989585e-01 | 0.701 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 1.995045e-01 | 0.700 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.995045e-01 | 0.700 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.995045e-01 | 0.700 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.033314e-01 | 0.692 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 2.033314e-01 | 0.692 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 2.037578e-01 | 0.691 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.071666e-01 | 0.684 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.073818e-01 | 0.683 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.073818e-01 | 0.683 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 2.073818e-01 | 0.683 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 2.091750e-01 | 0.679 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.094770e-01 | 0.679 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 2.140355e-01 | 0.670 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 2.140355e-01 | 0.670 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.148595e-01 | 0.668 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.157171e-01 | 0.666 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.157171e-01 | 0.666 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 2.157171e-01 | 0.666 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.157171e-01 | 0.666 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.157171e-01 | 0.666 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.225789e-01 | 0.653 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.225789e-01 | 0.653 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 2.239652e-01 | 0.650 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.239652e-01 | 0.650 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.239652e-01 | 0.650 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.239652e-01 | 0.650 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 2.239652e-01 | 0.650 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.239652e-01 | 0.650 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.239652e-01 | 0.650 | 0 | 0 |
| Methionine salvage pathway | R-HSA-1237112 | 2.239652e-01 | 0.650 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.239652e-01 | 0.650 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.283765e-01 | 0.641 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 2.283765e-01 | 0.641 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.303202e-01 | 0.638 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 2.321271e-01 | 0.634 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 2.321271e-01 | 0.634 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.321271e-01 | 0.634 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.321271e-01 | 0.634 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 2.321271e-01 | 0.634 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.321271e-01 | 0.634 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.323394e-01 | 0.634 | 1 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.380791e-01 | 0.623 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.380791e-01 | 0.623 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.394966e-01 | 0.621 | 1 | 1 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.402037e-01 | 0.619 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 2.402037e-01 | 0.619 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.422913e-01 | 0.616 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.428109e-01 | 0.615 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 2.450914e-01 | 0.611 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.481957e-01 | 0.605 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.481957e-01 | 0.605 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.481957e-01 | 0.605 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 2.481957e-01 | 0.605 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.481957e-01 | 0.605 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.481957e-01 | 0.605 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 2.481957e-01 | 0.605 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.481957e-01 | 0.605 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.481957e-01 | 0.605 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 2.481957e-01 | 0.605 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.536338e-01 | 0.596 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.561043e-01 | 0.592 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 2.561043e-01 | 0.592 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.561043e-01 | 0.592 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.614219e-01 | 0.583 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.614219e-01 | 0.583 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.639301e-01 | 0.579 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.639301e-01 | 0.579 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 2.639301e-01 | 0.579 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.639301e-01 | 0.579 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.639301e-01 | 0.579 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.639301e-01 | 0.579 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.639301e-01 | 0.579 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.648533e-01 | 0.577 | 1 | 0 |
| HIV Infection | R-HSA-162906 | 2.649822e-01 | 0.577 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 2.653170e-01 | 0.576 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.653170e-01 | 0.576 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.661737e-01 | 0.575 | 1 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.672978e-01 | 0.573 | 1 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.676640e-01 | 0.572 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.692122e-01 | 0.570 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 2.793370e-01 | 0.554 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.793370e-01 | 0.554 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 2.793370e-01 | 0.554 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 2.793370e-01 | 0.554 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.793370e-01 | 0.554 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.847858e-01 | 0.545 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 2.869198e-01 | 0.542 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 2.869198e-01 | 0.542 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.882943e-01 | 0.540 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.886754e-01 | 0.540 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.944233e-01 | 0.531 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.944233e-01 | 0.531 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 2.944233e-01 | 0.531 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 2.944233e-01 | 0.531 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.944233e-01 | 0.531 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 2.944233e-01 | 0.531 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.951824e-01 | 0.530 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 3.003287e-01 | 0.522 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.018483e-01 | 0.520 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.018483e-01 | 0.520 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.018483e-01 | 0.520 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.018483e-01 | 0.520 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 3.018483e-01 | 0.520 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 3.018483e-01 | 0.520 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 3.018483e-01 | 0.520 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 3.018483e-01 | 0.520 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 3.091956e-01 | 0.510 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 3.091956e-01 | 0.510 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 3.091956e-01 | 0.510 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.091956e-01 | 0.510 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 3.091956e-01 | 0.510 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.091956e-01 | 0.510 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.119511e-01 | 0.506 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.119511e-01 | 0.506 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 3.164660e-01 | 0.500 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.235333e-01 | 0.490 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.236604e-01 | 0.490 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 3.273835e-01 | 0.485 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 3.306588e-01 | 0.481 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 3.306588e-01 | 0.481 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.307794e-01 | 0.480 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.307794e-01 | 0.480 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.312280e-01 | 0.480 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 3.350665e-01 | 0.475 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.350665e-01 | 0.475 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.350665e-01 | 0.475 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.350665e-01 | 0.475 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 3.378240e-01 | 0.471 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.378240e-01 | 0.471 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.378240e-01 | 0.471 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 3.378240e-01 | 0.471 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.378240e-01 | 0.471 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 3.380435e-01 | 0.471 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 3.447949e-01 | 0.462 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 3.447949e-01 | 0.462 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 3.447949e-01 | 0.462 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 3.507649e-01 | 0.455 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 3.516928e-01 | 0.454 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 3.516928e-01 | 0.454 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.516928e-01 | 0.454 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 3.516928e-01 | 0.454 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 3.523551e-01 | 0.453 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 3.537336e-01 | 0.451 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 3.541577e-01 | 0.451 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.541577e-01 | 0.451 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.585185e-01 | 0.445 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 3.585185e-01 | 0.445 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 3.585185e-01 | 0.445 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.585185e-01 | 0.445 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.617419e-01 | 0.442 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 3.652727e-01 | 0.437 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 3.652727e-01 | 0.437 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 3.652727e-01 | 0.437 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.679504e-01 | 0.434 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.719563e-01 | 0.430 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.719563e-01 | 0.430 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.719563e-01 | 0.430 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.736633e-01 | 0.428 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 3.768096e-01 | 0.424 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.785699e-01 | 0.422 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.785699e-01 | 0.422 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 3.785699e-01 | 0.422 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.797240e-01 | 0.421 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.851142e-01 | 0.414 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.851142e-01 | 0.414 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.851142e-01 | 0.414 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.915900e-01 | 0.407 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.915900e-01 | 0.407 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.915900e-01 | 0.407 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.915900e-01 | 0.407 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 3.915900e-01 | 0.407 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 3.915900e-01 | 0.407 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 3.954361e-01 | 0.403 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 4.043390e-01 | 0.393 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 4.043390e-01 | 0.393 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 4.043390e-01 | 0.393 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 4.043390e-01 | 0.393 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 4.043390e-01 | 0.393 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.043390e-01 | 0.393 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 4.106135e-01 | 0.387 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 4.106135e-01 | 0.387 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 4.168223e-01 | 0.380 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 4.168223e-01 | 0.380 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 4.168223e-01 | 0.380 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.174486e-01 | 0.379 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 4.229661e-01 | 0.374 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 4.229661e-01 | 0.374 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 4.246974e-01 | 0.372 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.246974e-01 | 0.372 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 4.290456e-01 | 0.367 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 4.290456e-01 | 0.367 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 4.290456e-01 | 0.367 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 4.290456e-01 | 0.367 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.290456e-01 | 0.367 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 4.290456e-01 | 0.367 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 4.350613e-01 | 0.361 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 4.350613e-01 | 0.361 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 4.350613e-01 | 0.361 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 4.350613e-01 | 0.361 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.350613e-01 | 0.361 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 4.350613e-01 | 0.361 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.350613e-01 | 0.361 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.350613e-01 | 0.361 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.350613e-01 | 0.361 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.350613e-01 | 0.361 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 4.379181e-01 | 0.359 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 4.410141e-01 | 0.356 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 4.426129e-01 | 0.354 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.439431e-01 | 0.353 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 4.469045e-01 | 0.350 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 4.469045e-01 | 0.350 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 4.527332e-01 | 0.344 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 4.549261e-01 | 0.342 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.576580e-01 | 0.339 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.585008e-01 | 0.339 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.637020e-01 | 0.334 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.698553e-01 | 0.328 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.698553e-01 | 0.328 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 4.698553e-01 | 0.328 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 4.698553e-01 | 0.328 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.754435e-01 | 0.323 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 4.754435e-01 | 0.323 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 4.754435e-01 | 0.323 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.754435e-01 | 0.323 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 4.754435e-01 | 0.323 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 4.809169e-01 | 0.318 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 4.809732e-01 | 0.318 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.864449e-01 | 0.313 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 4.864449e-01 | 0.313 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 4.864449e-01 | 0.313 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 4.899734e-01 | 0.310 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.918592e-01 | 0.308 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.918592e-01 | 0.308 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 4.918592e-01 | 0.308 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.970111e-01 | 0.304 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.972168e-01 | 0.303 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.972168e-01 | 0.303 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 4.977914e-01 | 0.303 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.025182e-01 | 0.299 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 5.129550e-01 | 0.290 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 5.129550e-01 | 0.290 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 5.129550e-01 | 0.290 | 0 | 0 |
| Translation | R-HSA-72766 | 5.166781e-01 | 0.287 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.180914e-01 | 0.286 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 5.180914e-01 | 0.286 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 5.180914e-01 | 0.286 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 5.180914e-01 | 0.286 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.180914e-01 | 0.286 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.231740e-01 | 0.281 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.231740e-01 | 0.281 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.231740e-01 | 0.281 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 5.231740e-01 | 0.281 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.272745e-01 | 0.278 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 5.282033e-01 | 0.277 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 5.282033e-01 | 0.277 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 5.282033e-01 | 0.277 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 5.331798e-01 | 0.273 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.331798e-01 | 0.273 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 5.336670e-01 | 0.273 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 5.381042e-01 | 0.269 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.381042e-01 | 0.269 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 5.429769e-01 | 0.265 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.429769e-01 | 0.265 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.431451e-01 | 0.265 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 5.477986e-01 | 0.261 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.477986e-01 | 0.261 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 5.479429e-01 | 0.261 | 1 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.525696e-01 | 0.258 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 5.525696e-01 | 0.258 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.525696e-01 | 0.258 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 5.565724e-01 | 0.254 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 5.586448e-01 | 0.253 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.665846e-01 | 0.247 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.665846e-01 | 0.247 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.665846e-01 | 0.247 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 5.677647e-01 | 0.246 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 5.711585e-01 | 0.243 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.737694e-01 | 0.241 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 5.756845e-01 | 0.240 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 5.756845e-01 | 0.240 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.801630e-01 | 0.236 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.845945e-01 | 0.233 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 5.845945e-01 | 0.233 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 5.976120e-01 | 0.224 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 6.018604e-01 | 0.221 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.028846e-01 | 0.220 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.060641e-01 | 0.217 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 6.085256e-01 | 0.216 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 6.102238e-01 | 0.215 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 6.143398e-01 | 0.212 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.175071e-01 | 0.209 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.184126e-01 | 0.209 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.196257e-01 | 0.208 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 6.199923e-01 | 0.208 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 6.264303e-01 | 0.203 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.264303e-01 | 0.203 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.264303e-01 | 0.203 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.264303e-01 | 0.203 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 6.275448e-01 | 0.202 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.303761e-01 | 0.200 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 6.304838e-01 | 0.200 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.342805e-01 | 0.198 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.342805e-01 | 0.198 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.381439e-01 | 0.195 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 6.381439e-01 | 0.195 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 6.419668e-01 | 0.192 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.494924e-01 | 0.187 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.494924e-01 | 0.187 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 6.540349e-01 | 0.184 | 1 | 1 |
| Protein folding | R-HSA-391251 | 6.604869e-01 | 0.180 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.604869e-01 | 0.180 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 6.641144e-01 | 0.178 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 6.739579e-01 | 0.171 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 6.746148e-01 | 0.171 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 6.752985e-01 | 0.171 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 6.763822e-01 | 0.170 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.814580e-01 | 0.167 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.882855e-01 | 0.162 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 6.914554e-01 | 0.160 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.040246e-01 | 0.152 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 7.043016e-01 | 0.152 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.127154e-01 | 0.147 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.175645e-01 | 0.144 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 7.186697e-01 | 0.143 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.196141e-01 | 0.143 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.255160e-01 | 0.139 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.369519e-01 | 0.133 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.452168e-01 | 0.128 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 7.456511e-01 | 0.127 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 7.504107e-01 | 0.125 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.505828e-01 | 0.125 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.505828e-01 | 0.125 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.505828e-01 | 0.125 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 7.532235e-01 | 0.123 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 7.584218e-01 | 0.120 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 7.599839e-01 | 0.119 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 7.609800e-01 | 0.119 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 7.609800e-01 | 0.119 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 7.614052e-01 | 0.118 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 7.684941e-01 | 0.114 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 7.781853e-01 | 0.109 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 7.799378e-01 | 0.108 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 7.874031e-01 | 0.104 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.016442e-01 | 0.096 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.018845e-01 | 0.096 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.168727e-01 | 0.088 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 8.318501e-01 | 0.080 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.354000e-01 | 0.078 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.371470e-01 | 0.077 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.371470e-01 | 0.077 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 8.405858e-01 | 0.075 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.405858e-01 | 0.075 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.439524e-01 | 0.074 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.439524e-01 | 0.074 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.439524e-01 | 0.074 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 8.509556e-01 | 0.070 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.597541e-01 | 0.066 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 8.597541e-01 | 0.066 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 8.656198e-01 | 0.063 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.656198e-01 | 0.063 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.684605e-01 | 0.061 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 8.750172e-01 | 0.058 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.759849e-01 | 0.058 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 8.790829e-01 | 0.056 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 8.891386e-01 | 0.051 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.903179e-01 | 0.050 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.914848e-01 | 0.050 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.024955e-01 | 0.045 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 9.055767e-01 | 0.043 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.060243e-01 | 0.043 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.095350e-01 | 0.041 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.151651e-01 | 0.039 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 9.160689e-01 | 0.038 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.229636e-01 | 0.035 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.258621e-01 | 0.033 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 9.269837e-01 | 0.033 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.288826e-01 | 0.032 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.315335e-01 | 0.031 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.344089e-01 | 0.029 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.417120e-01 | 0.026 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.567236e-01 | 0.019 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.582256e-01 | 0.019 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.623676e-01 | 0.017 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.666461e-01 | 0.015 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.797601e-01 | 0.009 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.827470e-01 | 0.008 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.881877e-01 | 0.005 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.885656e-01 | 0.005 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.897404e-01 | 0.004 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.917421e-01 | 0.004 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.940368e-01 | 0.003 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.985911e-01 | 0.001 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999906e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999990e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.999998e-01 | 0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| HSF1 activation | R-HSA-3371511 | 1.110223e-16 | 15.955 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.110223e-16 | 15.955 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.110223e-16 | 15.955 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.110223e-16 | 15.955 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.110223e-16 | 15.955 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 5.551115e-16 | 15.256 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 5.551115e-16 | 15.256 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 5.551115e-15 | 14.256 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.217249e-15 | 14.206 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.884182e-15 | 14.230 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.264056e-14 | 13.486 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 8.770762e-14 | 13.057 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 8.448797e-14 | 13.073 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.610934e-13 | 12.793 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 2.494671e-13 | 12.603 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.559997e-13 | 12.255 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 6.892265e-13 | 12.162 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 6.892265e-13 | 12.162 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.288747e-12 | 11.890 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.325939e-12 | 11.877 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 3.084089e-12 | 11.511 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 4.060419e-12 | 11.391 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 4.807155e-12 | 11.318 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.889600e-12 | 11.162 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 6.889600e-12 | 11.162 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 8.742451e-12 | 11.058 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.138767e-11 | 10.944 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 1.450828e-11 | 10.838 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.367229e-11 | 10.864 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.450828e-11 | 10.838 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.837941e-11 | 10.736 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.607192e-11 | 10.584 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.607192e-11 | 10.584 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 2.902578e-11 | 10.537 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.620071e-11 | 10.441 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.620071e-11 | 10.441 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.932132e-11 | 10.405 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.551981e-11 | 10.256 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.551981e-11 | 10.256 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.829781e-11 | 10.166 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 7.536971e-11 | 10.123 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.907464e-11 | 10.050 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 8.907464e-11 | 10.050 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.020667e-10 | 9.991 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.020667e-10 | 9.991 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.240332e-10 | 9.906 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.501599e-10 | 9.823 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.811300e-10 | 9.742 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.678041e-10 | 9.572 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 3.114352e-10 | 9.507 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.706956e-10 | 9.431 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.152044e-10 | 9.382 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 4.434475e-10 | 9.353 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.786302e-10 | 9.320 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.204497e-10 | 9.284 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 6.140088e-10 | 9.212 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 9.919459e-10 | 9.004 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.797389e-09 | 8.745 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.797389e-09 | 8.745 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.815597e-09 | 8.741 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.815597e-09 | 8.741 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.033392e-09 | 8.692 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.590976e-09 | 8.587 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 2.698028e-09 | 8.569 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.918463e-09 | 8.535 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 3.205741e-09 | 8.494 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.207741e-09 | 8.376 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 4.634657e-09 | 8.334 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.906669e-09 | 8.309 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 5.481010e-09 | 8.261 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 5.756200e-09 | 8.240 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 5.756200e-09 | 8.240 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 5.756200e-09 | 8.240 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 5.803141e-09 | 8.236 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 6.238474e-09 | 8.205 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.468537e-09 | 8.189 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 8.795531e-09 | 8.056 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.931056e-09 | 8.049 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.161600e-08 | 7.935 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.225091e-08 | 7.912 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.472957e-08 | 7.832 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.495178e-08 | 7.825 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.856691e-08 | 7.731 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.823985e-08 | 7.739 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.103174e-08 | 7.677 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.439511e-08 | 7.613 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.439511e-08 | 7.613 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 3.235271e-08 | 7.490 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 3.235271e-08 | 7.490 | 0 | 0 |
| M Phase | R-HSA-68886 | 3.976288e-08 | 7.401 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 5.088578e-08 | 7.293 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.031208e-08 | 7.220 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 7.202770e-08 | 7.143 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.841118e-08 | 7.106 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 8.293990e-08 | 7.081 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 1.165842e-07 | 6.933 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.165842e-07 | 6.933 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.285089e-07 | 6.891 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.300858e-07 | 6.886 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.542132e-07 | 6.812 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.506639e-07 | 6.822 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.629708e-07 | 6.788 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.821184e-07 | 6.740 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.903082e-07 | 6.721 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.045048e-07 | 6.689 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 3.293248e-07 | 6.482 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.618962e-07 | 6.441 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.708752e-07 | 6.431 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.228601e-07 | 6.374 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 5.610331e-07 | 6.251 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 6.860308e-07 | 6.164 | 1 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 9.810778e-07 | 6.008 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.067234e-06 | 5.972 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.278770e-06 | 5.893 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.342066e-06 | 5.872 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.669354e-06 | 5.777 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.761352e-06 | 5.754 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.761352e-06 | 5.754 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.761352e-06 | 5.754 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.803156e-06 | 5.744 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.891622e-06 | 5.723 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.891622e-06 | 5.723 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.711127e-06 | 5.567 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.735199e-06 | 5.563 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.954647e-06 | 5.529 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 4.222366e-06 | 5.374 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.222366e-06 | 5.374 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.067632e-06 | 5.217 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 8.052695e-06 | 5.094 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.652910e-06 | 5.063 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.167325e-05 | 4.933 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.182139e-05 | 4.927 | 1 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.205517e-05 | 4.919 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.239289e-05 | 4.907 | 1 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.775133e-05 | 4.751 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.844907e-05 | 4.734 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 2.120460e-05 | 4.674 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.645426e-05 | 4.438 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.843792e-05 | 4.415 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.843792e-05 | 4.415 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 3.896918e-05 | 4.409 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.062517e-05 | 4.391 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.377674e-05 | 4.359 | 1 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.554296e-05 | 4.342 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.967984e-05 | 4.304 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 5.221111e-05 | 4.282 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.563359e-05 | 4.255 | 1 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 6.543887e-05 | 4.184 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 6.543887e-05 | 4.184 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 6.543887e-05 | 4.184 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 6.543887e-05 | 4.184 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 7.197723e-05 | 4.143 | 1 | 0 |
| Signaling by VEGF | R-HSA-194138 | 7.249060e-05 | 4.140 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.626127e-05 | 4.118 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 8.994816e-05 | 4.046 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 9.633648e-05 | 4.016 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.022704e-04 | 3.990 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.266289e-04 | 3.897 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.287163e-04 | 3.890 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.316962e-04 | 3.880 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 1.578648e-04 | 3.802 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 1.678123e-04 | 3.775 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.685981e-04 | 3.773 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.748550e-04 | 3.757 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 1.781803e-04 | 3.749 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.799869e-04 | 3.745 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.203076e-04 | 3.657 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.263235e-04 | 3.645 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 2.828648e-04 | 3.548 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.844499e-04 | 3.546 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.844499e-04 | 3.546 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.096410e-04 | 3.509 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.844499e-04 | 3.546 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 2.844499e-04 | 3.546 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 2.844499e-04 | 3.546 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.275662e-04 | 3.485 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 3.292938e-04 | 3.482 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.454781e-04 | 3.462 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.514662e-04 | 3.454 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 3.536986e-04 | 3.451 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.641735e-04 | 3.439 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.572252e-04 | 3.340 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 5.005689e-04 | 3.301 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 5.159865e-04 | 3.287 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.365294e-04 | 3.270 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 5.667018e-04 | 3.247 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 5.719431e-04 | 3.243 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 6.038532e-04 | 3.219 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 6.428675e-04 | 3.192 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 6.458837e-04 | 3.190 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 6.672777e-04 | 3.176 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.838080e-04 | 3.165 | 1 | 1 |
| Muscle contraction | R-HSA-397014 | 7.004317e-04 | 3.155 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 7.194756e-04 | 3.143 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 7.261176e-04 | 3.139 | 1 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 7.485362e-04 | 3.126 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 8.935356e-04 | 3.049 | 1 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.827378e-04 | 3.008 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.010078e-03 | 2.996 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.010078e-03 | 2.996 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.119800e-03 | 2.951 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.421818e-03 | 2.847 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.187670e-03 | 2.925 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.282877e-03 | 2.892 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.201523e-03 | 2.920 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.283130e-03 | 2.892 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.340031e-03 | 2.873 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.148324e-03 | 2.940 | 1 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.398888e-03 | 2.854 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.349658e-03 | 2.870 | 1 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.482692e-03 | 2.829 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.498794e-03 | 2.824 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.534379e-03 | 2.814 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.574935e-03 | 2.803 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.642774e-03 | 2.784 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.772483e-03 | 2.751 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.788353e-03 | 2.748 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.788353e-03 | 2.748 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.788353e-03 | 2.748 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.823676e-03 | 2.739 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.827747e-03 | 2.738 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.959064e-03 | 2.708 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.959064e-03 | 2.708 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.055540e-03 | 2.687 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.067103e-03 | 2.685 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.106109e-03 | 2.677 | 1 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.319812e-03 | 2.635 | 1 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.339681e-03 | 2.631 | 1 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.371440e-03 | 2.625 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.371440e-03 | 2.625 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 2.604877e-03 | 2.584 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.702132e-03 | 2.568 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.962598e-03 | 2.528 | 1 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 3.156437e-03 | 2.501 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 3.203811e-03 | 2.494 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 3.286156e-03 | 2.483 | 1 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.378404e-03 | 2.471 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 3.445466e-03 | 2.463 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.646301e-03 | 2.438 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 3.647907e-03 | 2.438 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 3.647907e-03 | 2.438 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 3.647907e-03 | 2.438 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 4.292410e-03 | 2.367 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.379288e-03 | 2.359 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 4.474031e-03 | 2.349 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.544395e-03 | 2.343 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 4.556478e-03 | 2.341 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.775147e-03 | 2.321 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.775823e-03 | 2.321 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 5.224192e-03 | 2.282 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 5.238614e-03 | 2.281 | 1 | 1 |
| Nef and signal transduction | R-HSA-164944 | 5.720339e-03 | 2.243 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 5.720339e-03 | 2.243 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 7.005317e-03 | 2.155 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 7.693492e-03 | 2.114 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.005317e-03 | 2.155 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.858859e-03 | 2.164 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 5.782160e-03 | 2.238 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 7.005317e-03 | 2.155 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 7.185823e-03 | 2.144 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 8.408290e-03 | 2.075 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 8.408290e-03 | 2.075 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 8.571658e-03 | 2.067 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 9.197823e-03 | 2.036 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 9.512963e-03 | 2.022 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 9.926195e-03 | 2.003 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 9.926195e-03 | 2.003 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 9.926195e-03 | 2.003 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 9.926195e-03 | 2.003 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.024349e-02 | 1.990 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.044179e-02 | 1.981 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.155603e-02 | 1.937 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 1.155603e-02 | 1.937 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.159161e-02 | 1.936 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.238044e-02 | 1.907 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 1.264079e-02 | 1.898 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.292494e-02 | 1.889 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.329484e-02 | 1.876 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.375568e-02 | 1.862 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.475173e-02 | 1.831 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 1.513973e-02 | 1.820 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.621272e-02 | 1.790 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.671720e-02 | 1.777 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.671720e-02 | 1.777 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.799967e-02 | 1.745 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 1.882228e-02 | 1.725 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.913645e-02 | 1.718 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.913645e-02 | 1.718 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.949899e-02 | 1.710 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 1.992738e-02 | 1.701 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.193095e-02 | 1.659 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.352409e-02 | 1.628 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.352409e-02 | 1.628 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.445052e-02 | 1.612 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.585783e-02 | 1.587 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.597971e-02 | 1.585 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 2.597971e-02 | 1.585 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.678544e-02 | 1.572 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.828138e-02 | 1.548 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 2.828138e-02 | 1.548 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.003192e-02 | 1.522 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 3.003192e-02 | 1.522 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.079222e-02 | 1.512 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.079222e-02 | 1.512 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 3.145244e-02 | 1.502 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 3.213761e-02 | 1.493 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.639835e-02 | 1.439 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 4.823576e-02 | 1.317 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 4.823576e-02 | 1.317 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 4.823576e-02 | 1.317 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 4.823576e-02 | 1.317 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 4.823576e-02 | 1.317 | 0 | 0 |
| NTF3 activates NTRK3 signaling | R-HSA-9034013 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 4.823576e-02 | 1.317 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 4.823576e-02 | 1.317 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 4.823576e-02 | 1.317 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.165936e-02 | 1.380 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.165936e-02 | 1.380 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 4.457024e-02 | 1.351 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 4.755418e-02 | 1.323 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 4.755418e-02 | 1.323 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.907327e-02 | 1.408 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 4.457024e-02 | 1.351 | 1 | 1 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 4.823576e-02 | 1.317 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 4.165936e-02 | 1.380 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.439752e-02 | 1.463 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 3.606584e-02 | 1.443 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.318719e-02 | 1.479 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 3.255228e-02 | 1.487 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.439752e-02 | 1.463 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.606584e-02 | 1.443 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 3.870949e-02 | 1.412 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 3.471011e-02 | 1.460 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 3.471011e-02 | 1.460 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 4.578252e-02 | 1.339 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 4.664198e-02 | 1.331 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 3.270574e-02 | 1.485 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.165936e-02 | 1.380 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.882379e-02 | 1.411 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.035294e-02 | 1.394 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 4.733653e-02 | 1.325 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 3.907327e-02 | 1.408 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.842562e-02 | 1.315 | 1 | 1 |
| Syndecan interactions | R-HSA-3000170 | 5.060897e-02 | 1.296 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.060897e-02 | 1.296 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 5.491386e-02 | 1.260 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 5.548679e-02 | 1.256 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 5.691434e-02 | 1.245 | 1 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 5.692243e-02 | 1.245 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 5.692243e-02 | 1.245 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 5.692243e-02 | 1.245 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 5.692243e-02 | 1.245 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.992848e-02 | 1.222 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.992848e-02 | 1.222 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.992848e-02 | 1.222 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.992848e-02 | 1.222 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.017689e-02 | 1.221 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.017689e-02 | 1.221 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 6.017689e-02 | 1.221 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 6.282039e-02 | 1.202 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 6.282039e-02 | 1.202 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.282039e-02 | 1.202 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.349376e-02 | 1.197 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 6.349376e-02 | 1.197 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 6.513366e-02 | 1.186 | 1 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.687103e-02 | 1.175 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 6.903187e-02 | 1.161 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 7.030674e-02 | 1.153 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.030674e-02 | 1.153 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.030674e-02 | 1.153 | 1 | 1 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 7.030674e-02 | 1.153 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.030674e-02 | 1.153 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 7.147827e-02 | 1.146 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 7.147827e-02 | 1.146 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 7.147827e-02 | 1.146 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 7.147827e-02 | 1.146 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 7.213348e-02 | 1.142 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 7.225974e-02 | 1.141 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.322464e-02 | 1.135 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.379897e-02 | 1.132 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.734581e-02 | 1.112 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.734581e-02 | 1.112 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.734581e-02 | 1.112 | 1 | 1 |
| Generic Transcription Pathway | R-HSA-212436 | 7.807153e-02 | 1.108 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 7.893211e-02 | 1.103 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 7.893211e-02 | 1.103 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 8.001949e-02 | 1.097 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 8.001949e-02 | 1.097 | 0 | 0 |
| IRS activation | R-HSA-74713 | 8.288685e-02 | 1.082 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 8.288685e-02 | 1.082 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 8.288685e-02 | 1.082 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 8.288685e-02 | 1.082 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 8.288685e-02 | 1.082 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 8.288685e-02 | 1.082 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 8.459597e-02 | 1.073 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.459597e-02 | 1.073 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 8.829570e-02 | 1.054 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 9.415596e-02 | 1.026 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 9.415596e-02 | 1.026 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 1.052873e-01 | 0.978 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 1.052873e-01 | 0.978 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 1.162825e-01 | 0.934 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.162825e-01 | 0.934 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 1.162825e-01 | 0.934 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.162825e-01 | 0.934 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.271433e-01 | 0.896 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.271433e-01 | 0.896 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 1.271433e-01 | 0.896 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.271433e-01 | 0.896 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.378712e-01 | 0.861 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.484680e-01 | 0.828 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.484680e-01 | 0.828 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.589351e-01 | 0.799 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 1.589351e-01 | 0.799 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.692743e-01 | 0.771 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 1.443396e-01 | 0.841 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.701721e-01 | 0.769 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.745515e-01 | 0.758 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.117842e-01 | 0.952 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.117842e-01 | 0.952 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.446537e-01 | 0.840 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 9.204286e-02 | 1.036 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.154285e-01 | 0.938 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.771958e-01 | 0.752 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 1.484680e-01 | 0.828 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.378712e-01 | 0.861 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.484680e-01 | 0.828 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.197095e-01 | 0.922 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 9.204286e-02 | 1.036 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.154285e-01 | 0.938 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 1.162825e-01 | 0.934 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.271433e-01 | 0.896 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 1.692743e-01 | 0.771 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 1.154285e-01 | 0.938 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.194617e-01 | 0.923 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.276307e-01 | 0.894 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 1.361546e-01 | 0.866 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 1.745515e-01 | 0.758 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 9.415596e-02 | 1.026 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.591923e-01 | 0.798 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.317636e-01 | 0.880 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.162825e-01 | 0.934 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 1.271433e-01 | 0.896 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.484680e-01 | 0.828 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 1.589351e-01 | 0.799 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 1.154285e-01 | 0.938 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.400950e-01 | 0.854 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.484680e-01 | 0.828 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.359270e-01 | 0.867 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.074721e-01 | 0.969 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.589351e-01 | 0.799 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.711317e-01 | 0.767 | 0 | 0 |
| Translation | R-HSA-72766 | 1.078744e-01 | 0.967 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.484680e-01 | 0.828 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 1.692743e-01 | 0.771 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.402621e-01 | 0.853 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 9.204286e-02 | 1.036 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.035520e-01 | 0.985 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.745515e-01 | 0.758 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.676842e-01 | 0.776 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.692743e-01 | 0.771 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.528580e-01 | 0.816 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.162825e-01 | 0.934 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.692743e-01 | 0.771 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.235295e-01 | 0.908 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.335057e-01 | 0.875 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.504150e-01 | 0.823 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 9.415596e-02 | 1.026 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 9.415596e-02 | 1.026 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 9.415596e-02 | 1.026 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 1.378712e-01 | 0.861 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 1.378712e-01 | 0.861 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.359270e-01 | 0.867 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.528580e-01 | 0.816 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.475251e-01 | 0.831 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 1.074721e-01 | 0.969 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.261371e-01 | 0.899 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 1.271433e-01 | 0.896 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.378712e-01 | 0.861 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 1.614721e-01 | 0.792 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 9.657958e-02 | 1.015 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.695901e-01 | 0.771 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.484680e-01 | 0.828 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.015486e-01 | 0.993 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.716145e-01 | 0.765 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.482867e-01 | 0.829 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.091890e-01 | 0.962 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.484680e-01 | 0.828 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.562490e-01 | 0.806 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 1.418012e-01 | 0.848 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.271433e-01 | 0.896 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.359270e-01 | 0.867 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.359270e-01 | 0.867 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.484680e-01 | 0.828 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.589351e-01 | 0.799 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 1.401194e-01 | 0.854 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.378712e-01 | 0.861 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.317636e-01 | 0.880 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.401194e-01 | 0.854 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 9.204286e-02 | 1.036 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.378841e-01 | 0.860 | 1 | 1 |
| Influenza Infection | R-HSA-168255 | 1.005924e-01 | 0.997 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 9.967266e-02 | 1.001 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.390749e-01 | 0.857 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 1.589351e-01 | 0.799 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.194617e-01 | 0.923 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.359270e-01 | 0.867 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.615893e-01 | 0.792 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.789489e-01 | 0.747 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.794869e-01 | 0.746 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.794869e-01 | 0.746 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.794869e-01 | 0.746 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.794869e-01 | 0.746 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.794869e-01 | 0.746 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 1.794869e-01 | 0.746 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 1.794869e-01 | 0.746 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 1.794869e-01 | 0.746 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.794869e-01 | 0.746 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 1.794869e-01 | 0.746 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 1.794869e-01 | 0.746 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.797121e-01 | 0.745 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.833188e-01 | 0.737 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.833188e-01 | 0.737 | 1 | 1 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.833188e-01 | 0.737 | 1 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.877935e-01 | 0.726 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.877935e-01 | 0.726 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.877935e-01 | 0.726 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.894977e-01 | 0.722 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.895375e-01 | 0.722 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 1.895747e-01 | 0.722 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.895747e-01 | 0.722 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.895747e-01 | 0.722 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.922386e-01 | 0.716 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.923594e-01 | 0.716 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.926072e-01 | 0.715 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.966975e-01 | 0.706 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 1.988644e-01 | 0.701 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.995390e-01 | 0.700 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.995390e-01 | 0.700 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.995390e-01 | 0.700 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.995390e-01 | 0.700 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.995390e-01 | 0.700 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.995390e-01 | 0.700 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.995390e-01 | 0.700 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.995390e-01 | 0.700 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.995390e-01 | 0.700 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 1.995390e-01 | 0.700 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.995390e-01 | 0.700 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 2.071289e-01 | 0.684 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 2.093814e-01 | 0.679 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 2.093814e-01 | 0.679 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.093814e-01 | 0.679 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.093814e-01 | 0.679 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.093814e-01 | 0.679 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.093814e-01 | 0.679 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.093814e-01 | 0.679 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.093814e-01 | 0.679 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 2.093814e-01 | 0.679 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 2.093814e-01 | 0.679 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.093814e-01 | 0.679 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 2.093814e-01 | 0.679 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 2.093814e-01 | 0.679 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 2.101472e-01 | 0.677 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 2.147135e-01 | 0.668 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 2.191034e-01 | 0.659 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.191034e-01 | 0.659 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 2.191034e-01 | 0.659 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 2.191034e-01 | 0.659 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 2.191034e-01 | 0.659 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.191034e-01 | 0.659 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 2.191648e-01 | 0.659 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 2.236863e-01 | 0.650 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 2.287064e-01 | 0.641 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 2.287064e-01 | 0.641 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 2.287064e-01 | 0.641 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.287064e-01 | 0.641 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 2.287064e-01 | 0.641 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.340700e-01 | 0.631 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 2.340700e-01 | 0.631 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 2.377048e-01 | 0.624 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.381920e-01 | 0.623 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.381920e-01 | 0.623 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 2.381920e-01 | 0.623 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 2.381920e-01 | 0.623 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.381920e-01 | 0.623 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 2.381920e-01 | 0.623 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 2.418361e-01 | 0.616 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.438644e-01 | 0.613 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.457293e-01 | 0.610 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.463854e-01 | 0.608 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.475614e-01 | 0.606 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.475614e-01 | 0.606 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.475614e-01 | 0.606 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 2.475614e-01 | 0.606 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.509379e-01 | 0.600 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.518505e-01 | 0.599 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 2.537242e-01 | 0.596 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.542882e-01 | 0.595 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 2.554928e-01 | 0.593 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.568162e-01 | 0.590 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.568162e-01 | 0.590 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.568162e-01 | 0.590 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 2.568162e-01 | 0.590 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 2.568162e-01 | 0.590 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.568162e-01 | 0.590 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.600493e-01 | 0.585 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 2.600493e-01 | 0.585 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 2.659578e-01 | 0.575 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.659578e-01 | 0.575 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 2.659578e-01 | 0.575 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.659578e-01 | 0.575 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.659578e-01 | 0.575 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.659578e-01 | 0.575 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.659578e-01 | 0.575 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.659578e-01 | 0.575 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.691645e-01 | 0.570 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 2.737217e-01 | 0.563 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.749874e-01 | 0.561 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.749874e-01 | 0.561 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 2.749874e-01 | 0.561 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.749874e-01 | 0.561 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 2.749874e-01 | 0.561 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 2.749874e-01 | 0.561 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.749874e-01 | 0.561 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 2.782779e-01 | 0.556 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.839065e-01 | 0.547 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 2.839065e-01 | 0.547 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.839065e-01 | 0.547 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.839065e-01 | 0.547 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 2.839065e-01 | 0.547 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 2.873841e-01 | 0.542 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.919329e-01 | 0.535 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 2.919329e-01 | 0.535 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 2.927165e-01 | 0.534 | 1 | 1 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 2.927165e-01 | 0.534 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 2.927165e-01 | 0.534 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 2.927165e-01 | 0.534 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.927165e-01 | 0.534 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.927165e-01 | 0.534 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 2.951126e-01 | 0.530 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 3.014186e-01 | 0.521 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 3.014186e-01 | 0.521 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.014186e-01 | 0.521 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 3.014186e-01 | 0.521 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 3.014186e-01 | 0.521 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 3.014186e-01 | 0.521 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.014186e-01 | 0.521 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.037031e-01 | 0.518 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 3.100141e-01 | 0.509 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.100141e-01 | 0.509 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.100141e-01 | 0.509 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 3.100141e-01 | 0.509 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.100141e-01 | 0.509 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.100141e-01 | 0.509 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 3.146105e-01 | 0.502 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.171388e-01 | 0.499 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 3.185044e-01 | 0.497 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 3.185044e-01 | 0.497 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.185044e-01 | 0.497 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.185044e-01 | 0.497 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.185044e-01 | 0.497 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 3.236400e-01 | 0.490 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.268908e-01 | 0.486 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 3.268908e-01 | 0.486 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 3.268908e-01 | 0.486 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.351745e-01 | 0.475 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.351745e-01 | 0.475 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 3.351745e-01 | 0.475 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 3.351745e-01 | 0.475 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 3.351745e-01 | 0.475 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.351745e-01 | 0.475 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 3.351745e-01 | 0.475 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.433567e-01 | 0.464 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.433567e-01 | 0.464 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.433567e-01 | 0.464 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.433567e-01 | 0.464 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 3.433567e-01 | 0.464 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 3.433567e-01 | 0.464 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 3.433567e-01 | 0.464 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 3.433567e-01 | 0.464 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.460739e-01 | 0.461 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 3.505329e-01 | 0.455 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 3.514388e-01 | 0.454 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 3.514388e-01 | 0.454 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.514388e-01 | 0.454 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 3.540951e-01 | 0.451 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 3.549816e-01 | 0.450 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.574474e-01 | 0.447 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.594196e-01 | 0.444 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 3.594218e-01 | 0.444 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 3.594218e-01 | 0.444 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 3.594218e-01 | 0.444 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 3.638465e-01 | 0.439 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.673071e-01 | 0.435 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.673071e-01 | 0.435 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.673071e-01 | 0.435 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.673071e-01 | 0.435 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 3.673071e-01 | 0.435 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.674896e-01 | 0.435 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 3.708315e-01 | 0.431 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.708315e-01 | 0.431 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 3.726653e-01 | 0.429 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 3.750958e-01 | 0.426 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.750958e-01 | 0.426 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 3.770566e-01 | 0.424 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.785337e-01 | 0.422 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.827891e-01 | 0.417 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.858007e-01 | 0.414 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.903881e-01 | 0.409 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.978941e-01 | 0.400 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 3.978941e-01 | 0.400 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.978941e-01 | 0.400 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.978941e-01 | 0.400 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.978941e-01 | 0.400 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 3.978941e-01 | 0.400 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.978941e-01 | 0.400 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.978941e-01 | 0.400 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.988163e-01 | 0.399 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 3.988163e-01 | 0.399 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 4.007041e-01 | 0.397 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.031266e-01 | 0.395 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 4.031266e-01 | 0.395 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 4.053081e-01 | 0.392 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 4.053081e-01 | 0.392 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.053081e-01 | 0.392 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.053081e-01 | 0.392 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.053081e-01 | 0.392 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 4.117033e-01 | 0.385 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 4.126312e-01 | 0.384 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.126312e-01 | 0.384 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 4.126312e-01 | 0.384 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 4.126312e-01 | 0.384 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 4.126312e-01 | 0.384 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 4.126312e-01 | 0.384 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.171939e-01 | 0.380 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 4.198647e-01 | 0.377 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.198647e-01 | 0.377 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 4.198647e-01 | 0.377 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 4.198647e-01 | 0.377 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 4.198647e-01 | 0.377 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 4.237350e-01 | 0.373 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 4.237350e-01 | 0.373 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 4.270094e-01 | 0.370 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.340667e-01 | 0.362 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 4.340667e-01 | 0.362 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 4.340667e-01 | 0.362 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 4.340667e-01 | 0.362 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.340667e-01 | 0.362 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.340667e-01 | 0.362 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 4.340667e-01 | 0.362 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 4.340667e-01 | 0.362 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.410374e-01 | 0.356 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.410374e-01 | 0.356 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.410374e-01 | 0.356 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 4.410374e-01 | 0.356 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 4.410374e-01 | 0.356 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 4.410374e-01 | 0.356 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 4.410374e-01 | 0.356 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 4.479227e-01 | 0.349 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 4.479227e-01 | 0.349 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.479227e-01 | 0.349 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.479227e-01 | 0.349 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 4.479227e-01 | 0.349 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.536357e-01 | 0.343 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.536357e-01 | 0.343 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 4.547236e-01 | 0.342 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 4.547236e-01 | 0.342 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 4.547236e-01 | 0.342 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.547236e-01 | 0.342 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.547236e-01 | 0.342 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.547236e-01 | 0.342 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.547236e-01 | 0.342 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 4.547236e-01 | 0.342 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 4.614412e-01 | 0.336 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 4.615143e-01 | 0.336 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 4.680764e-01 | 0.330 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.680764e-01 | 0.330 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.739588e-01 | 0.324 | 1 | 1 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 4.739588e-01 | 0.324 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.746303e-01 | 0.324 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.746303e-01 | 0.324 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 4.811038e-01 | 0.318 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 4.811038e-01 | 0.318 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.811038e-01 | 0.318 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.811038e-01 | 0.318 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.811038e-01 | 0.318 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.811038e-01 | 0.318 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.811038e-01 | 0.318 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.811038e-01 | 0.318 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.874979e-01 | 0.312 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.874979e-01 | 0.312 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.874979e-01 | 0.312 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.874979e-01 | 0.312 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.874979e-01 | 0.312 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.874979e-01 | 0.312 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.874979e-01 | 0.312 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 4.898871e-01 | 0.310 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.938137e-01 | 0.306 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 4.938137e-01 | 0.306 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 5.000520e-01 | 0.301 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.062138e-01 | 0.296 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 5.062138e-01 | 0.296 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.062138e-01 | 0.296 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.062138e-01 | 0.296 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 5.062138e-01 | 0.296 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 5.123000e-01 | 0.290 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 5.123000e-01 | 0.290 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 5.123000e-01 | 0.290 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 5.182118e-01 | 0.285 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 5.183116e-01 | 0.285 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 5.183116e-01 | 0.285 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.183116e-01 | 0.285 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.242494e-01 | 0.280 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.242494e-01 | 0.280 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 5.242494e-01 | 0.280 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.242494e-01 | 0.280 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 5.242494e-01 | 0.280 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.301144e-01 | 0.276 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 5.301144e-01 | 0.276 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 5.301144e-01 | 0.276 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 5.359075e-01 | 0.271 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 5.416295e-01 | 0.266 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.416295e-01 | 0.266 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 5.472813e-01 | 0.262 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.472813e-01 | 0.262 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.472813e-01 | 0.262 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.472813e-01 | 0.262 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 5.528638e-01 | 0.257 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 5.528638e-01 | 0.257 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 5.528638e-01 | 0.257 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.583778e-01 | 0.253 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 5.638241e-01 | 0.249 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.648347e-01 | 0.248 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.692036e-01 | 0.245 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.692036e-01 | 0.245 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.692036e-01 | 0.245 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.692036e-01 | 0.245 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.692036e-01 | 0.245 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.718834e-01 | 0.243 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.718834e-01 | 0.243 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.745170e-01 | 0.241 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 5.745170e-01 | 0.241 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.745170e-01 | 0.241 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.745170e-01 | 0.241 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 5.797653e-01 | 0.237 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.797653e-01 | 0.237 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 5.797653e-01 | 0.237 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.797653e-01 | 0.237 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.849491e-01 | 0.233 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 5.900693e-01 | 0.229 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.900693e-01 | 0.229 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.951267e-01 | 0.225 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.951267e-01 | 0.225 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 5.956982e-01 | 0.225 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 6.025770e-01 | 0.220 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 6.050559e-01 | 0.218 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 6.050559e-01 | 0.218 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 6.099293e-01 | 0.215 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.124345e-01 | 0.213 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 6.144280e-01 | 0.212 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 6.156788e-01 | 0.211 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 6.170559e-01 | 0.210 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.194972e-01 | 0.208 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.194972e-01 | 0.208 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 6.194972e-01 | 0.208 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 6.194972e-01 | 0.208 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.221052e-01 | 0.206 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 6.221052e-01 | 0.206 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.241933e-01 | 0.205 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.241933e-01 | 0.205 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.241933e-01 | 0.205 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 6.241933e-01 | 0.205 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.288317e-01 | 0.201 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 6.315898e-01 | 0.200 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 6.334131e-01 | 0.198 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.334131e-01 | 0.198 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 6.334131e-01 | 0.198 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 6.378097e-01 | 0.195 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 6.379382e-01 | 0.195 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.424078e-01 | 0.192 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 6.424078e-01 | 0.192 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.468225e-01 | 0.189 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.511829e-01 | 0.186 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 6.511829e-01 | 0.186 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 6.554898e-01 | 0.183 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 6.554898e-01 | 0.183 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.554898e-01 | 0.183 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 6.554898e-01 | 0.183 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.554898e-01 | 0.183 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 6.589338e-01 | 0.181 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.639454e-01 | 0.178 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 6.639454e-01 | 0.178 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.762432e-01 | 0.170 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 6.818610e-01 | 0.166 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.841919e-01 | 0.165 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 6.855780e-01 | 0.164 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.880931e-01 | 0.162 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.919464e-01 | 0.160 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.919464e-01 | 0.160 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.957523e-01 | 0.158 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.032244e-01 | 0.153 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 7.068916e-01 | 0.151 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 7.105138e-01 | 0.148 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.176251e-01 | 0.144 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 7.176251e-01 | 0.144 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 7.176251e-01 | 0.144 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 7.245625e-01 | 0.140 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.313303e-01 | 0.136 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 7.346519e-01 | 0.134 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 7.411731e-01 | 0.130 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 7.411731e-01 | 0.130 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 7.411731e-01 | 0.130 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 7.411731e-01 | 0.130 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 7.506570e-01 | 0.125 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.597950e-01 | 0.119 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 7.657012e-01 | 0.116 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.713150e-01 | 0.113 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.714628e-01 | 0.113 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.742905e-01 | 0.111 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 7.742905e-01 | 0.111 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.742905e-01 | 0.111 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.770834e-01 | 0.110 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.798420e-01 | 0.108 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.798420e-01 | 0.108 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.879154e-01 | 0.104 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.931333e-01 | 0.101 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.941334e-01 | 0.100 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.956942e-01 | 0.099 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 8.031891e-01 | 0.095 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 8.080330e-01 | 0.093 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 8.080330e-01 | 0.093 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.127583e-01 | 0.090 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 8.150774e-01 | 0.089 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 8.150774e-01 | 0.089 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 8.240714e-01 | 0.084 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.407743e-01 | 0.075 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 8.558986e-01 | 0.068 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.662958e-01 | 0.062 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 8.728091e-01 | 0.059 | 0 | 0 |
| S Phase | R-HSA-69242 | 8.728091e-01 | 0.059 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.759463e-01 | 0.058 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.774859e-01 | 0.057 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 8.790065e-01 | 0.056 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 8.905144e-01 | 0.050 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 9.103642e-01 | 0.041 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.136658e-01 | 0.039 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.247695e-01 | 0.034 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.266299e-01 | 0.033 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.272871e-01 | 0.033 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.502516e-01 | 0.022 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.641077e-01 | 0.016 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.724375e-01 | 0.012 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.756973e-01 | 0.011 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.768912e-01 | 0.010 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.917945e-01 | 0.004 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.936310e-01 | 0.003 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.953027e-01 | 0.002 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.961175e-01 | 0.002 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.963566e-01 | 0.002 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.970794e-01 | 0.001 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.972856e-01 | 0.001 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.988870e-01 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.989287e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999602e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999983e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | 0.000 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.000000e+00 | 0.000 | 1 | 1 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.000000e+00 | 0.000 | 1 | 1 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 1.000000e+00 | 0.000 | 1 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.000000e+00 | 0.000 | 1 | 1 |
| Other interleukin signaling | R-HSA-449836 | 1.000000e+00 | 0.000 | 1 | 1 |
| Interleukin-6 family signaling | R-HSA-6783589 | 1.000000e+00 | 0.000 | 1 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 1.000000e+00 | 0.000 | 1 | 1 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.000000e+00 | 0.000 | 1 | 1 |
| Interleukin-20 family signaling | R-HSA-8854691 | 1.000000e+00 | 0.000 | 1 | 1 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.000000e+00 | 0.000 | 1 | 1 |
| Interleukin-23 signaling | R-HSA-9020933 | 1.000000e+00 | 0.000 | 1 | 1 |
| Interleukin-27 signaling | R-HSA-9020956 | 1.000000e+00 | 0.000 | 1 | 1 |